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Chapter 1 of this manuscript is a literature review that serves as an introduction
to the entire dissertation. Chapter 2 examines the effects of the melatonin injection on
heart rate and rhythmicity in Drosophila melanogaster Canton-S (wild-type) pupae and
pupae bearing a variety of heart mutations. Chapter 3 investigates further the possible
mechanisms of melatonin’s ability to increase heart rhythmicity without significantly
affecting heart rate. A melatonin antagonist, luzindole; a high-affinity melatonin
agonist, 2-iodomelatonin and RNAi techniques are used to identify a possible melatonin
receptor in Drosophila melanogaster.
An appendix contains a previously published manuscript detailing experiments
performed at the beginning of my graduate studies before I began my work with
melatonin. The paper is entitled The Relationship of Heart Function to Temperature in
Drosophila melanogaster and its Heritability (Jennings et al., 2009).
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INTRODUCTION

MELATONIN AND ITS EFFECTS ON VERTEBRATE AND INVERTEBRATE
PHYSIOLOGY
Cardiovascular disease is the leading cause of death (~598,000 per year) in the
United States (Heron, 2013), thus elucidating causes is of principal importance for
public health. Furthermore, there are several categories of this disease, including
cardiomyopathy, conduction defects, hypertension, atherosclerosis, and venous
malformations, many of which are caused by genes that are conserved and may act in
common physiological processes or pathways (Bier & Bodmer, 2004). Acute coronary
occlusion is the leading cause of morbidity and mortality in the Western world.
According to the World Health Organization, it will be the major cause of death in the
world by the year 2020 (Lopez & Murray, 1998). Cardiac events can result in damage
to the intrinsic pacemaker cells of the heart, causing a variety of cardiac arrhythmias.
Postoperative atrial fibrillation (AF) is a specific type of arrhythmia that is the most
common complication after cardiac surgery (Zeriouh et al., 2014). Furthermore, it is
well understood that cardiac arrhythmias are a common and often lethal manifestation of
many acquired and inherited diseases affecting the cardiovascular system.
Electrophysiologists have long sought to understand and treat the arrhythmogenic
mechanisms of these diseases to sustain life and improve its quality (Delisle et al.,
2004).
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Drosophila as a model organism for the study of cardiovascular disease
The study of heart development and physiology in Drosophila melanogaster is
intensifying rapidly as it continues to expand as a model system for studying cardiac
problems generally and genetic influences in particular. Findings in the fly are directly
applicable to the human heart as a growing number of genes have been identified with
homologous function in both organisms (Bier & Bodmer, 2004). Although heart
structure in Drosophila is very different from that of vertebrates, many of the basic
elements for cardiac specification and differentiation are conserved. Of the 1682 human
disease genes currently known, 74% have homologs in Drosophila and nearly a third of
these genes (~500) are as highly conserved as genes known to be functionally equivalent
between flies and humans (Bier & Bodmer, 2004). These Drosophila genes include
homologs of genes causing a broad spectrum of human diseases ranging from
neurological disorders and cancer to developmental defects, metabolic/storage disorders,
cardiovascular disease, as well as genes required for function of the visual, auditory, and
immune systems (Reiter et al., 2001). Because of the simplicity in its structure and
availability of powerful genetic tools, the Drosophila heart has emerged as a model
system for unraveling the basic genetic and molecular mechanisms of cardiac
development, function, and aging (Qian et al., 2007).
Anatomy and physiology of the Drosophila heart
The Drosophila heart, or dorsal vessel, is located medially and dorsally in the
hemocoel and transports hemolymph through the larval and adult body cavity (Miller,
1950; Rizki, 1978; Curtis et al., 1999). The anterior third of the dorsal vessel forms the
aorta. The posterior segment, or heart proper, contains three pairs of openings called
ostia to admit hemolymph (Rizki, 1978; Curtis et al., 1999; Wasserthal, 2007). Heart
2

pacemaking in Drosophila is myogenic (Dowse et al., 1995; Gu & Singh, 1995; Bodmer
et al., 2005), and originates from a caudal pacemaker (Rizki, 1978), an assembly of ion
channels, including those passing Ca2+ and K+, interacting in an oscillatory manner
(Dowse et al., 1995; Johnson et al., 1998; Bodmer et al., 2005). The possibility of a
second, more anterior pacemaker in the region of the cardiovascular valve is suggested
by reversals in contraction seen occasionally in larvae and consistently in early pupae
(McCann, 1969; Rizki, 1978). Heartbeat is triphasic, consisting of contraction (systole),
relaxation (diastole), and pause (diastasis) (Jones, 1977; Rizki, 1978; Curtis et al., 1999;
Wasserthal, 2007). Heart rate is determined by the duration of diastasis (Markou &
Theophilidis, 2000) and is modulated by temperature (Irisawa et al., 1993; Dowse et al.,
1995), small peptide hormones (Johnson et al., 2000), and neurotransmitters (Miller,
1985; Dascal et al., 1986; Johnson et al., 1997; Hille, 2001). Cardioactive substances
alter heart rate and rhythmicity by altering pacemaker ion channel kinetics either by
direct binding or indirect modulation through signaling pathways (Johnson et al., 1997;
Johnson et al., 2000; Johnson et al., 2002).
Four ion channel genes have been identified as necessary for normal heartbeat
through analysis of mutant heartbeat and pharmacology (Johnson et al., 1998; Johnson et
al., 2000). Three of the channels allow the passage of K+ and the other carries a Ca2+
current (Johnson et al., 2000). Johnson et al. (1997, 1998) proposed a model for the
Drosophila cardiac pacemaker based on genetic and pharmacological data: A delayedrectifier potassium channel current (IKr) containing an α subunit encoded by ether à gogo (eag) (Kaplan & Trout, 1969; Warmke et al., 1991a; Engel & Wu, 1992;
Brüggemann et al., 1993) creates a hyperpolarizing leak. The decay of the
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hyperpolarizing K+ efflux has the effect of depolarizing sino-atrial cells so that a
voltage-gated calcium channel, the α1 subunit of which may be encoded by cacophony
(cac) (Von Schilcher, 1976; Smith et al., 1996; Smith et al., 1998), opens to allow Ca2+
to enter the cell. This current is blocked by -conotoxin (-CgTx) MVIIC, an
antagonist of N- (Ashcroft, 2000; Hille, 2001) and P/Q-type calcium channels, and
importantly this agent is effective at disrupting the normal heartbeat of Drosophila
(Olivera et al., 1994). Subsequently, this influx of calcium opens a calcium-activated
potassium channel encoded by slowpoke (Elkins et al., 1986) and blocked by
charybdotoxin (CTX) (Moczydlowski et al., 1988), and a fast voltage-gated potassium
channel (KV, A-type) encoded by Shaker (Sh) (Kaplan & Trout, 1969; Warmke &
Ganetzky, 1994) and blocked by 4-aminopyridine (4-AP) (Thompson, 1977;
Moczydlowski et al., 1988; Engel & Wu, 1992). The efflux of potassium repolarizes the
membrane (Thompson, 1977; Elkins et al., 1986; Fozzard, 1986; Irisawa et al., 1993;
Littleton & Ganetzky, 2000; Lipsius et al., 2001). The eag channel is also activated by
the calcium depolarization, but in a more delayed fashion. The K+ current carried by
this channel type eventually triggers the pacemaker potential, thereby recommencing the
oscillatory process.
Mutations affecting heart function in Drosophila
As noted above, there are several genes in Drosophila that encode ion channels
and calcium signaling pathways involved in pacemaker function of the heart. Human
homologues of these genes have also been identified. The gene ether à-go-go (eag)
(Brüggemann et al., 1993) encodes a K+ channel (Kaplan & Trout, 1969; Warmke et al.,
1991; Bruggemann et al., 1993; Silverman et al., 2003). Flies bearing the eag mutant
4

exhibited heart beating irregularity at several test temperatures (Johnson et al., 1998).
This gene has a homologue in humans known as HERG (Human eag Related Gene)
(Warmke & Ganetzky, 1994), and mutations at this locus result in a cardiac
arrhythmicity--Chromosome 7-linked long QT (LQT2) syndrome (Keating &
Sanguinetti, 1996; Sanguinetti et al., 1996). Mutations in the kumbakharna gene in the
fly, encoding the Sarcoplasmic Endoplasmic Reticulum Calcium ATPase (SERCA)
produce severe cardiac defects (Sanyal et al., 2006) while several diseases that arise
from defective SERCA function have been described in mammals; cardiac disorders are
known to be associated with reduced SERCA2a function in cardiac muscles of higher
vertebrates (MacLennan, 2000; Periasamy & Huke, 2001). It is well known that
potassium channels are central to generation and possibly conduction of the heartbeat in
Drosophila. Slowpoke (slo) is a mutation which encodes the pore-forming structural
portion of a Ca2+ activated K+ channel in Drosophila melanogaster (Atkinson et al.,
1991). The role of the Ca2+-dependent K+ current (ICF) is particularly critical in
pacemaking of the heart (Johnson et al., 1998). The mutation slo virtually eliminates
heartbeat by abolishing ICF (Elkins et al., 1986; Johnson et al., 1998). Pallanck &
Ganetzky (1994), report the cloning of mouse and human homologs of the Drosophila
melanogaster calcium-activated potassium channel gene, slowpoke (slo). Both the
human and mouse genes encode polypeptides that have more than 50% amino acid
identities with their Drosophila counterpart. no action potential temperature sensitive (napts) is
a recessive mutation that affects the level of sodium channel activity and, at high
temperature, causes paralysis associated with a loss of action potentials. napts is a gainof-function allele of maleless (mle), a gene required for X chromosome dosage
compensation and male viability (Kernan et. al, 1991). napts slows heartbeat and renders
5

it less rhythmic and prevents the heart from responding to temperature with an altered
rate (Dowse et al., 1995). mle is highly homologous to human RNA helicase A and the
bovine counterpart of RNA helicase A, nuclear helicase II, proteins implicated in the
unwinding of RNA (Lee et al., 1997). The mutation dunce (dnc1), encodes a cAMPspecific phosphodiesterase (PDE), which has adverse effects on learning and memory in
Drosophila. cAMP-PDE also interacts with the calcium-calmodulin signaling pathway.
This signaling pathway is also modulated by melatonin (Turjanski et al., 2004).
Modulation of this signaling pathway changes the concentration of intracellular calcium.
Calcium signaling is vital to heart function in both Drosophila and humans. Four
human genes (DPDE1 through DPDE4) are closely related to the dnc locus of
Drosophila (Bolger et al., 1993).
Homologies between vertebrate and Drosophila heart development

These parallels extend to heart development. The discovery of the homeobox
transcription factor Tinman in Drosophila and its conservation in vertebrates provided
the first evidence that heart development was controlled by homologous pathways in the
animal kingdom (Bodmer, 1993; Azpiazu & Frasch, 1993). The NK-2 type homeoboxcontaining gene tinman (tin) (Kim & Nirenberg, 1989), is essential for early molecular
events initiating cardiac development in Drosophila (Bodmer, 1993; Bier & Bodmer,
2004). A tin homolog, NKX2-5, has been strongly implicated as the cause of a
developmental atrial septal defect and atrioventricular nodal dysfunction (Schott et al.,
1998). The key determinants of cardiogenesis in the fly also play fundamental roles in
early cardiac specification in the vertebrates, and they do so in similar ways (Bier &
Bodmer, 2004). For example, in flies and vertebrates, Dpp/bone morphogenetic protein
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(BMP)-TGF-h signals cross germ layers to maintain Tinman/NKX2-5 expression
(Frasch, 1995; Schultheiss et al., 1997; Lockwood & Bodmer, 2002). A similar
relationship exists between Tinman/NKX2-5 and Pannier/GATA-4 (Klinedinst &
Bodmer, 2003; Garg et al., 2003). Moreover, mutations have been identified in humans
in many of these conserved heart-specifying genes, such as NKX2-5, GATA-4, and
TBX-5, which cause various forms of congenital heart disease (Basson et al., 1997;
Schott et al., 1998; Garg et al., 2003). Because the control of early cardiac development
and function is likely to be carried out by conserved networks of target genes, many
congenital heart diseases, even those for which a major player has been identified, are
likely to be multigenic (Ranade et al., 2003; Kraft & de Andrade, 2003).
Of particular interest to me are the effects of the indolamine melatonin (N-acetyl5-methoxytryptamine) on the pacemaker of Drosophila melanogaster.
Neurotransmitters and neurohormones are central to control of heart function in
Drosophila. Prior research in our lab has shown that heart rate in the pupa of D.
melanogaster is significantly increased by serotonin (5-hydroxytryptamine, 5-HT)
(Johnson et al., 1998). Furthermore, four 5-HT receptors have been identified and
sequenced in Drosophila melanogaster, strongly indicating a physiological purpose for
this neurotransmitter (Saudou et al., 1992; Colas et al., 1995).
Because of the strong antagonistic relationship between serotonin and melatonin
in regulating circadian rhythms (see below), and the fact that they are both synthesized
from similar precursors, my interests focus on the effects that melatonin might have on
the pacemaker activity and heart function of D. melanogaster. It was hypothesized that
the acceleratory effect of serotonin would be paired with a deceleratory effect by
melatonin. Surprisingly, unpublished studies of D. melanogaster and melatonin
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performed by Evelyn Powers and me between 2009 and the present have shown that
melatonin has no significant effect on heart rate, but significantly increases rhythmicity
in hearts that were either beating normally or substantially arrhythmic before treatment
with melatonin.
Melatonin
In 1958, Lerner et al. successfully isolated a substance from pineal extracts,
which had been shown to lighten the skin color of tadpoles, frogs, toads, and fish
(McCord & Allen, 1917; Kitay & Altschule, 1954). Melatonin, a ubiquitously present,
low molecular weight molecule in living organisms, has a simple structure; however, it
exhibits pleiotropic biological activities in species from bacteria to mammals (Hardeland
et al., 2011). In vertebrates, the roles of melatonin are numerous and include: regulating
circadian rhythm and acting as a neuromodulator, hormone, cytokine and biological
response modifier (Man et al., 2011; Reiter, 1991). It also affects brain, immune,
gastrointestinal, cardiovascular, renal, bone and endocrine functions, and acts as an
oncostatic and anti-aging molecule (Yu et al., 1993; Pandi-Perumal et al., 2008;
Slominski et al., 2008; Leja-Szpak et al., 2010; Celinski et al., 2011). Some of these
activities are receptor-mediated, including via melatonin membrane receptors and
nuclear receptors (Reppert, 1997; Dubocovich et al., 1999; Dubocovich & Markowska,
2005; Imbesi et al., 2009; Shiu et al., 2010). Other functions are melatonin receptor
independent (Reiter, 1996; Tan et al., 2002) including the interactions of melatonin with
reactive oxygen species (ROS) and those mediated by its bioactive metabolites (Silva et
al., 2004, 2005; Mayo et al., 2005; Manda et al., 2007, 2008; Hardeland et al., 2009;
Schaefer & Hardeland 2009). Melatonin is an indolamine which is biologically
synthesized from the amino acid L-Tryptophan. Serotonin is a precursor to melatonin.
8

Melatonin release in mammals, birds and reptiles varies in a daily cycle, as does
serotonin, and is well known for its key role in regulating circadian rhythms. In
mammals, a circadian clock in the suprachiasmatic nucleus (SCN) of the hypothalamus
receives information from the retina about environmental light. The clock controls a
rhythm of the enzyme hydroxyindole-O-methyltransferase (HIOMT), which Omethylates N-acetylserotonin to produce melatonin in the final step of melatonin
synthesis. This information passes through the neural circuits of the superior cervical
ganglia and controls rhythmic melatonin release by the pineal gland. Melatonin then
travels through the blood stream and binds to melatonin receptors located throughout the
body. Melatonin levels are highest at night, when serotonin levels are at their lowest.
As we are exposed to daylight, serotonin levels increase and melatonin levels decline.
In addition to the pineal gland, some melatonin is synthesized in the Harderian
gland of rats (Bubenik et al., 1976), retina of chickens (Iuvone et al., 2002), bone
marrow of rats and humans (Conti et al., 2000), gastrointestinal tract of humans, birds
and rodents (Lee & Pang, 1993) and lacrimal glands of Syrian hamsters (Mhatre et al.,
1988). Rat and pig studies by Bubenik et al., 1996 confirmed early findings of Huether
and coworkers (1992) that concentrations of melatonin are substantially higher in
gastrointestinal tract tissues than in plasma. Interestingly, at any time of the day or
night, the gut of humans contains at least 400 times more melatonin than the pineal
gland (Chen et al., 2011). In humans endogenous melatonin is released from the pineal
gland into the bloodstream and then into other bodily fluids, including cerebral spinal
fluid, saliva, and bile (Head, 2005). Blood (endogenous) melatonin is mainly bound to
albumin (70%) and to a lesser extent to orosomucoid (Morin et al., 1997).
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Orosomucoid is a glycoprotein in the blood plasma that functions in carrying lipophilic
compounds, such as melatonin. Circulating melatonin can reach all body tissues and is
able to cross the blood–brain barrier to modulate brain activity (Hirata et al., 1974).
During the day human serum concentrations of the hormone are low (10-20
pg/ml), and significantly increase at night (80-120 pg/ml) with peak between 24:00 and
03:00 h. The onset of secretion is usually around 21:00-22:00 h and the offset at 07:0009:00 h (Karasek et al., 1998).
Exogenous melatonin is rapidly absorbed in humans when taken orally and peak
serum levels are observed at 60-150 minutes. Peak concentrations after oral dosing of
80mg of crystalline melatonin are significantly higher (350 to 10,000 times) than those
seen with endogenous melatonin secretion (Waldhauser et al., 1984). Exogenous plasma
melatonin displays a short half-life. Kinetic studies of circulating melatonin following
intravenous or subcutaneous bolus administration demonstrated an elimination phase
with a half –life (t ½) of 44 minutes in humans (Iguichi et al., 1982), 30 minutes in
rhesus monkeys (Reppert et al., 1979), 20 to 24 minutes in rats (Ozaki et al., 1976;
Gibbs & Vriend, 1981; Chan et al., 1984), and 13 to 14 minutes in Syrian hamsters
(Vaughan et al., 1986). Endogenous melatonin is mainly metabolized in the liver to 6OH-melatonin and excreted as conjugates of sulfuric and glucuronic acid (Kveder,
1961). About 90% of endogenous melatonin is excreted in urine as 6sulfatoxymelatonin (aMT6s) with a plasma half-life of 10–45 minutes (Arendt, 1995).
Exogenous and endogenous melatonin are both metabolized and excreted via the same
pathways, but the bioavailability of exogenous melatonin from an oral dose ranges from
10-56 percent.
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The low bioavailability of exogenous melatonin is thought to be a consequence of
hepatic first-pass extraction, which converts melatonin to its metabolite before it enters
the systemic circulation (Di et al., 1997).
Melatonin receptors
There have been two membrane bound melatonin receptors identified and
characterized in humans, MT1 and MT2. MT1 was known as Mel1a, and MT2 as Mel1b
( Dubocovich et al., 2010, 1998). Both of them belong to the family of G proteincoupled, seven transmembrane receptors (GPCRs) (Dubocovich et al., 2003; WittEnderby et al., 2003). However, melatonin is also lipophilic, which allows it to enter the
nucleus directly and bind to nuclear receptors in the RORα/RZR family (Slominski et
al., 2012).
In humans, MT1 receptors are expressed in the brain, cardiovascular system
(including peripheral blood vessels, aorta and heart), immune system, testes, ovary, skin,
liver, kidney, adrenal cortex, placenta, breast, retina, pancreas and spleen (Dubocovich
& Markowska, 2005; Fischer et al., 2008; Pandi-Perumal et al., 2008; Slominski et al.,
2005, 2008). In the brain, the receptor is predominantly found in the hypothalamus,
cerebellum, hippocampus, substantia nigra and ventral tegmental area (Pandi-Perumal et
al., 2008). MT2 receptors have been found in the immune system, brain (hypothalamus,
suprachiasmatic nucleus (SCN)), retina, pituitary, blood vessels, testes, kidney,
gastrointestinal tract, mammary glands, adipose tissue, and the skin (Dubocovich et al.,
2005; Reppert et al., 1995; Roca et al., 1996; Slominski et al., 2005). It is highly likely
that if the melatonin receptor is present in D. melanogaster, it will also be a GPCR.
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At present, 35 GPCRs are functionally characterized in Drosophila. Another 14
receptors are predicted to be involved in neuropeptide signaling pathways, but their
ligands are still unknown and therefore they are classified as “orphan” receptors (Caers
et al., 2012).
Effects of melatonin
Melatonin’s many effects in humans include its hypnotic/sedative effects, its
ability to shift circadian rhythms when administered at appropriate times of the day, its
ability to modulate the immune system by increasing T lymphocyte, natural killer cell,
eosinophil and cytokine production (Lissoni et al., 1993), and its ability to slow cancer
growth by inhibiting mitosis and inducing apoptosis of some cancer cells (Blask et al.,
2002). Melatonin is a powerful antioxidant that stimulates gene expression and
activities of superoxide dimutase, catalase, and glutathione peroxidase; all of which play
a role in the metabolism of H2O2 which ultimately results in reducing the formation of
the devastatingly toxic OH radical (Reiter, 1996). Owing to its antioxidant properties,
melatonin also shows beneficial anti-aging effects in rats (Poeggeler, 2005). Melatonin
may also act at the level of the mitochondrial respiratory chain to reduce electron
leakage and, therefore, free radical generation (Reiter et al., 2002). The cardioprotective effects of melatonin (Tan et al., 2002) are of particular interest and will be
discussed in more detail shortly.
Early melatonin research focused on its synthesis and metabolic pathways,
specifically in relation to its day/night cycle, its improvement of thyroid function in perimenopausal and menopausal women, its ability to lighten skin pigmentation in
amphibians (McCord & Allen, 1917; Kitay & Altschule, 1954), its beneficial effects on
behavioral and sleep disorders in human subjects, and its key roles in the modulation of
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the endocrine system including regulation of GnRH (gonadotrophin releasing hormone)
release, stimulation of oxytocin secretion, promotion of progesterone synthesis release,
regulation of cortisol production, and promotion of androgen production (Balík et al.,
2004; Schaeffer & Sirotkin, 1997; Tamura et al., 2008, 2009). Models used in early
research included predominately humans and avian species, but most research on
melatonin and its cardiovascular effects in mammals has been carried out in humans and
rats.
Since the identification of melatonin by Lerner et al. (1958), it has been shown
that melatonin is involved in the regulation of many physiological systems, including the
cardiovascular system (Vazan et al., 2003;2005). Minimal research has been done on
the effects of exogenous melatonin in the human cardiovascular system. The results
obtained thus far show that melatonin improves cardiovascular health, however, the
question remains as to whether melatonin’s effects on cardiovascular function are
antioxidant in nature or receptor mediated. It is well known that melatonin is a potent
antioxidant, even more powerful than vitamins C and E. In 2002, Reiter and Tan
showed that melatonin exhibits cardio-protective effects in rat hearts exposed to
ischemia and then re-perfused. Cagnaccie et al., (1998) and Arangino et al., (1999)
found that the oral administration of melatonin in comparison to placebo was able to
reduce blood pressure, vascular reactivity (vasorelaxant effect), and catecholamines in
healthy young women and men. These data suggest that melatonin administration may
induce beneficial effects on the circulation of humans and subjects may be protected
against cardiovascular accidents with regular melatonin supplementation. In the study
completed by Cagnacci et al., (1998), the cardiovascular effects induced by the daytime
administration of melatonin (1 mg) were compared with those of placebo in 17 young,
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healthy, early follicular-phase women. Compared with placebo, the administration of
melatonin modified, within 90 min, the pulsatility index (PI) of the internal carotid
artery, abdominal aorta, and axillary artery. The pulsatility index is a measure of the
variability of blood velocity in a vessel evaluated by color Doppler ultrasound. In a
subsequent, two day study (Arangino et al., 1999), 14 normal, healthy men were given
either 1 mg of melatonin or placebo on Day 1 and then, on Day 2, received the opposite
treatment (as compared to the treatment they received on Day 1). Ninety minutes after
supplementation on both days the researchers measured blood flow in a blood vessel
(PI) in the arm as well as blood pressure in both groups. The administration of
melatonin significantly reduced blood pressure, the PI in the internal carotid artery, and
catecholamine levels within 90 minutes. Melatonin reduces blood pressure in young
men (Arangino et al. 1999), reduces myocardial contractility via a specific cardiac
receptor in rat papillary muscle (Abete et al., 1997), and increases the antioxidant
(glutathione peroxidase) activity in the plasma and erythrocytes of spontaneously
hypertensive rats (Girouard et al., 2004). In addition, decreased melatonin levels were
reported in various pathological conditions including hypertension with “nondipper
pattern” (which means that blood pressure is independent of the sleep-wakefulness
cycle), aggravation of heart failure, ischemic heart disease, and in patients after acute
myocardial infarction (Paulis & Simko, 2007). Also, patients with coronary heart
disease have lower than normal melatonin levels (Dominguez-Rodriguez & AbreuGonzalez, 2010). Interestingly, incidence of sudden cardiac death is high in the morning
hours when melatonin levels are low (Sahna et al., 2006).
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Melatonin mechanisms of action
The mechanisms by which melatonin exerts its protective effects are not clearly
understood. It is evident that melatonin is a very powerful antioxidant, and therefore has
the ability to scavenge free radicals that can damage tissues. In recent years, research
has shifted its focus to melatonin’s powerful antioxidant properties as they relate to
cardiovascular health. Melatonin is a powerful scavenger of reactive oxygen species
(ROS), including the hydroxyl (Reiter, Tan et. al., 1998) and peroxyl radicals (Pieri et
al., 1994) as well as singlet oxygen (Sewerynek et al., 1996) and nitric oxide (Noda et
al., 1999). ROS are known to play a role in the formation of neurodegenerative and
cardiovascular disease and cancer. The possibility exists that melatonin may have the
ability to prevent such disease processes. In addition to scavenging ROS, melatonin
stimulates the antioxidant enzymes superoxide dismutase, glutathione peroxidase, and
catalase (Head, 2005). Melatonin was also able to reduce lipid peroxidation more
effectively than vitamin C or E (Gitto et al., 2001). Lipid peroxidation is the process
whereby lipids undergo oxidative degradation. In this process, free radicals steal
electrons from the phospholipids in the cell membrane and cause cell damage. The
antioxidant properties of melatonin in vivo are demonstrated by the ability of melatonin
to reduce ischemia-reperfusion injury in various organs of rats, including the heart (Tan
et al., 1998), kidney (Sahna et al., 2005), brain (Cho et al., 1997) and liver (Sewerynek et
al., 1996). Using the rat as a model, various experiments have been carried out in which
pharmacological or physiological levels of melatonin have been used to protect the heart
against ischemia-reperfusion (I/R) injury. This refers to the tissue damage that is caused
after the blood supply returns to a tissue that has experienced a period of oxygen
deprivation. In these studies, either exogenous melatonin was administered before,
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during and after I/R injury to the heart, or the rats were pinealectomized to reduce
endogenous levels of melatonin. The results showed a significant reduction in damage
due to oxidative stress clearly owing to the concentration of melatonin. It was shown
that the presence of melatonin reduced premature ventricular contractions and
ventricular fibrillation, reduced ventricular tachycardia, reduced lipid peroxidation and
lowered OH radical generation, reduced reperfusion arrhythmias and infarct volume and
lowered mortality (Paulis & Simko, 2007). In addition to melatonin’s protective effects
of cardiac tissue, its protective effects of other tissue types have also been researched. In
the in vivo brain (including the spinal cord), liver, kidney, gastrointestinal tract, lung and
placenta, the amount of tissue damage and the severity of compromised function after
I/R were shown to be reduced when melatonin was employed as an ameliorative agent.
Furthermore, the damage inflicted by other agents that induce high oxidative stress is
reduced when melatonin is exogenously administered (Paulis & Simko, 2007).
There is also evidence that melatonin’s cardio-protective effects may be receptor
mediated. In 2006, Rezanni et al., looked at the beneficial effects of melatonin in
protecting against cyclosporine-A (CsA)-induced cardio-toxicity. When melatonin and
CsA were injected along with luzindole, a melatonin receptor antagonist, it showed that
the protective effects of melatonin were lost when the animals received the melatonin
receptor antagonist. Melatonin’s cardio-protective effects against myocardial
ischemia/reperfusion (MI/R) injury in rats was were blocked by luzindole in
experiments performed by Yu et al., in 2014.
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Luzindole also abolished the short and long term cardio-protective effects of melatonin
administered both before, during and after induced myocardial ischemia in rats
(Lochner, 2006). Luzindole was also shown to block melatonin’s ability to reduce blood
pressure by binding to ML1 receptors in the anterior hypothalamic area (AHA) of the rat
brain (Ding et al., 2001).
There are several non-specific mechanisms of melatonin action as well, which
are unrelated to its antioxidant properties. Melatonin is thought to modulate the
calcium/calmodulin signaling pathway either by changing intracellular Ca2+
concentration via activation of its G-protein–coupled membrane receptors, or through a
direct interaction with calmodulin (CaM) (Turjanski et al., 2004). CaM is known to
interact with a large number of proteins important for Ca2+ -dependent intracellular
signaling, thus enabling the cell to control biological processes as diverse as muscle
contraction, fertilization, cell proliferation, vesicular fusion, and apoptosis (Berridge et
al., 1998). Satake et al., (1991) found that the inhibition of Ca2+ channels by melatonin
causes vasorelaxation in the isolated rat aorta. Chen et al., (1993) found that there are
time-dependent changes in [Ca2+ + Mg2+]-dependent ATPase activity that are absent in
pinealectomized or light-exposed rats, and that in-vitro studies of cardiac tissue
incubated in the presence of melatonin over a wide range of doses showed that
melatonin stimulated the Ca2+ pump. These findings suggest that the daily change in
[Ca2+ + Mg2+]-dependent ATPase activity in the sarcolemma of heart tissue is a result of
the circadian rhythm in pineal melatonin production and secretion. These findings may
be applicable to understanding normal cardiac physiology.
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Melatonin research with Drosophila
Some melatonin research has been done using Drosophila melanogaster as a
model. Arylalkylamine N-acetyltransferases (AANATs) are enzymes which catalyze
the rate limiting step in melatonin synthesis in the vertebrate pineal gland. More
specifically, conversion of serotonin (5-hydroxytryptomine; 5-HT) to N-acetylserotonin,
the precursor of the circadian neurohormone melatonin, is catalyzed by serotonin Nacetyltransferase (AANAT) in a reaction requiring acetyl coenzyme A (AcCoA)
(Hickman et al., 1999). Two different AANATs (AANAT1 and AANAT2) have been
identified and characterized in Drosophila melanogaster (Hintermann & Meyer, 1995;
Brodbeck et al., 1998; Amherd et al., 2000). A second enzyme, HIOMT, involved in Omethylating N-acetylserotonin in the final step of the melatonin synthesis pathway, has
not yet been discovered in Drosophila.
Four receptors for 5-HT have been described in Drosophila: one shares sequence
homology to the vertebrate 5HT receptor type 2 (5HT2R; CG1056), one is similar to the
vertebrate serotonin receptor type 7 (5HT7R; CG12073) and two show high homology to
vertebrate 5HT1 type receptor (5HT1AR and 5HT1BR; CG16720 and CG15113,
respectively) (Silva et al., 2014). Computed gene (CG) numbers were used for genes
identified during the annotation of the whole Drosophila genome sequence (Vaudry &
Seong, 2014). Drosophila melanogaster synthesizes its own serotonin (Livingstone,
1981) and also has several clusters of serotonergic neurons located in its central nervous
system (Valles, 1988).
Bonilla et al., (2006) found that melatonin was more effective than serotonin,
lipoic acid and ascorbic acid at counteracting paraquat-induced oxidative stress in D.
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melanogaster. In another pesticide exposure study, flies exposed to rotenone exhibited
the neurodegenerative and behavioral deficits classically seen in Parkinson’s disease
(PD). Melatonin introduced into the feeding medium alleviated both symptomatic
impairment and neuronal loss, supporting the idea that this agent may be beneficial in
the treatment of PD (Coulom & Birman, 2004). In further examination of melatonin’s
antioxidant properties, a wild-type strain of D. melanogaster was exposed to the catalase
inhibitor 3-amino-1,2,4-triazole in an effort to enhance oxidative stress from endogenous
sources. While most of the flies that were fed inhibitor alone died, flies fed a
combination of inhibitor and melatonin had a much higher survival rate (Coto-Montes
and Hardeland, 1999). In addition to its protective effects, several studies have shown
that melatonin-fed flies have a significantly increased lifespan (Li & Xu, 1997;
Izmaylov & Obukhova, 1999; Bonilla et al., 2002; Anisimov, 2003; Terán et al., 2012).
The mechanism by which melatonin exerts its effects in D. melanogaster is not
known. Because there had been no melatonin receptors identified in the fruit fly when I
began my research, it was unclear whether melatonin acted only as a powerful
antioxidant and free radical scavenger or had other, receptor-mediated effects that may
be directly or indirectly regulating pacemaker activity. I proposed to conduct a series of
experiments that would allow me further to explore melatonin’s effects on pacemaker
activity, emphasizing both genetics and pharmacology, and was eager to determine
whether melatonin receptors are present in Drosophila melanogaster. Based on
preliminary research in our lab that showed melatonin’s effects on rhythmicity in wildtype hearts (Powers, unpublished), prior research identifying melatonin receptors and the
effects of melatonin in various organ systems of human and other mammalian models,
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and known homologies between the Drosophila and human genomes, I hypothesized
that Drosophila melanogaster does have at least one melatonin receptor and that
pacemaker activity is modulated by melatonin at the receptor level. If pacemaker
activity is in fact modulated by melatonin at the receptor level in Drosophila, this will
give us more clues about the mechanisms of melatonin’s action in improving and
protecting the human cardiovascular system.
Overview of research objectives
There has been no reported research to date that examines the antioxidant or other
effects of melatonin on heart function in Drosophila melanogaster. An Honor’s student
in our lab carried out a series of experiments where wild-type Drosophila pupae were
injected with varying concentrations of melatonin. Heart rate and rhythmicity were
recorded and compared before and after injection. Results of these experiments showed
no change in heart rate, but a significant increase in rhythmicity in previously
arrhythmic hearts (Powers, unpublished). Although these results were not reported, they
sparked my interest as to the mechanisms behind the rhythmicity increase.
The goals of my dissertation research have been twofold: 1. to examine the effects of
melatonin on heart rhythmicity and frequency in various strains of Drosophila
melanogaster, both wild-type and those bearing mutations affecting cardiac function.
2. to identify a melatonin receptor in Drosophila melanogaster and, therefore, elucidate
whether melatonin’s action is antioxidant related or receptor mediated. I believe that by
combining genetics and pharmacology, the mechanism of melatonin action can be better
understood.
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Effects of melatonin on heart rate and rhythmicity
In chapter 1, I examined the response of Canton S (CS) (Drosophila
melanogaster wild- type flies) to injections of varying concentrations of melatonin (0,
50 µM, 100 µM, 500 µM, 1000 µM and 2500 µM). With these data, I constructed a
dose-response curve that allowed me to determine the most effective concentration of
melatonin to use in subsequent experiments (1000 µM). Once this was determined, I
injected the optimal concentration of melatonin into various strains of Drosophila that
have a variety of different heart mutations, looking for a possible “rhythmicity rescue”
of the mutation by melatonin. Since these mutations cause genetically-based alterations
of heart physiology (usually pacemaker ion channels), rescuing an effect of a mutation
with melatonin strongly implicates receptor-mediated activity of melatonin.
The mutations I tested were no action potential temperature sensitive (napts),
Ca-P60A Kumbhakarna 170 (SERCA170), slowpoke (slo), dunce (dnc1) and ether-a-go-go
(eag). These particular heart mutations involve variations either in ion channel activity
or in intracellular calcium concentrations of the Drosophila pacemaker.

After my initial testing of the Drosophila mutant slo, I compared a dose response
in this animal to that of CS wild-type flies by injecting slo pupae with the same
concentrations of melatonin as described above (0, 50 µM, 100 µM, 500 µM, 1000 µM
and 2500 µM).

The next set of experiments involved crossing the slo mutant with the df [slo]
(slowpoke deficiency) strain. Deficiency stocks comprise chromosomal deletions which
provide definitive null alleles for the genes they uncover on the sister chromosome and
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are used to gauge the severity of any particular allele; indeed, the classical test for
defining an amorphic or null allele is to assess whether the homozygous phenotype is as
severe as when the allele is hemizygous with a deletion (Roote and Russell 2012). First
generation (F1) progeny of this stock were injected with the optimal concentration of
melatonin and the resulting rhythmicity index and frequency were analyzed.
My final set of experiments compared the effects serotonin, melatonin’s
precursor, with the effects of melatonin on heart rate and rhythmicity. Previous
experiments carried out by Johnson et al.,1997, showed that serotonin significantly
increased heart rate without increasing heart rhythmicity. Serotonin exerts its positive
chronotropic effects by binding to 5-HT2 receptors that have been identified in the larval
heart and aorta of Drosophila melanogaster (Majeed et al., 2014).
Melatonin receptor identification
The experiments described in the chapter 2 consist of a combination of
pharmacological and genetic techniques designed to identify a possible melatonin
receptor in Drosophila melanogaster and, therefore, determine whether melatonin’s
effects on heart rhythmicity are antioxidant related or receptor mediated.
Pharmacological experiments
Receptor identification often involves administration of known antagonists or
agonists to the ligand in question. If melatonin is increasing heart rhythmicity in
Drosophila by binding to a receptor, an antagonist acting at the receptor level, such as
luzindole, will block these effects. Similarly, injection of a melatonin receptor agonist,
such as 2-iodomelatonin, may mimic melatonin’s effects.
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The first set of experiments involved double injections of melatonin and
luzindole in Canton-S, slowpoke and napts Drosophila pupae. Injection Protocol: first
inject pupa with 2500 µM luzindole, allow to rest for 1.5 minutes, then inject pupa with
1000 µM melatonin and immediately begin heart recording lasting for 10 minutes.
The second set of experiments involved injection of 1000 µM 2-iodomelatonin
only in Canton-S and slowpoke pupae. Injection Protocol: an initial 10 minute preinjection heart recording is followed by injection, then a 10 minute post-injection heart
recording.

My final set of pharmacological experiments involved the injection of another
known powerful antioxidant, ascorbic acid (vitamin C) in order to investigate further the
mechanism of melatonin’s effects on heart rhythmicity. Melatonin is a very powerful
antioxidant that was found to be more effective than vitamin C or vitamin E in
combating paraquat induced oxidative stress in Drosophila melanogaster (Bonilla et al.,
2006).

Canton-S (wild-type) and slowpoke (mutant) flies were injected with the 1000

µM ascorbic acid which was also dissolved in calcium free ringers with 1% ETOH.
Heart rhythmicity index and frequency results were then compared to those of Canton-S
and slo flies that were injected with calcium-ringers with 1% ETOH (controls). 2iodomelatonin and melatonin.
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RNAi Experiments
Ribonucleic Acid Interference (RNAi) is a process that permits elimination of
expression of targeted gene sequences in an attempt to understand their function (Bellés,
2010). RNAi strains of orphan G-protein coupled receptors were crossed with a GMH5
driver that effectively silenced the gene in question in cardiac tissue. I chose four
Drosophila orphan GPCRs to test: CG4313, CG3171, CG13579, CG13575. These
specific strains were chosen because they come from a structural class of GPCRs that
are known to bind substances that are structurally similar to melatonin.

Figure I.1: The Generation of RNAi from dsRNA is completed as follows (a) the
experimentally derived dsRNA binds to the enzyme dicer which cleaves the dsRNA at
targeted sites (b). The coupling of a RISC to target mRNA creates cleavage (c) small
subunits of mRNA (d) that are able to effectively silence targeted genes (Bellés, 2010).
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CHAPTER 1
THE EFFECTS OF MELATONIN ON Drosophila HEART RATE AND
RHYTHMICITY

Abstract

Melatonin (N-acetyl-5-methoxytryptamine), has been shown to have both cardioprotective and anti-arrhythmic properties in vertebrates largely owing to its powerful
antioxidant properties. Very few studies have attributed improvements in cardiovascular
health to the binding of melatonin to its receptors (MT1 and MT2). In the present study,
micro molar concentrations of melatonin injected into the P1 pupae of Drosophila
melanogaster wild type and the following heart mutants (slo, dnc1, eag, naptsand CaP60AKum170) show acute and profoundly significant increases in heart rhythmicity across
all subjects ranging from 54-104 % without significantly affecting heart rate of these
animals. Effects of melatonin were also compared to injections of the melatonin
precursor serotonin (5-hydroxytryptamine), where serotonin significantly increases heart
rate in wild type and slo without significantly increasing heart rhythmicity. In
conclusion, the acute antiarrhythmic effects of melatonin injection in Drosophila
melanogaster are likely receptor-mediated based on the combination of collective data
from the experiments performed in Chapters 1 & 2.

Introduction

There are a variety of causes of cardiovascular disease ranging from inherited
conditions that alter heart structure or cause dysfunction in pacemaker ion channels, to
ischemic cardiac events that result in damage to heart tissue from oxidative stress and
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subsequent remodeling of heart structures. Furthermore, these diseases, whether
inherited or acquired, are associated with different types of heart arrhythmias that alter
overall function of the heart and often lead to sudden cardiac death. Clinical and
pathologic findings suggest that patients with conditions such as coronary artery disease,
cardiomyopathy, cardiac rhythm disturbances, or hypertensive heart disease are at high
risk of SCD (Roberts, 1990). Abnormal heart rhythms, notably atrial and ventricular
fibrillation, are leading causes of death and disability. Between 0.5 million and 1 million
North Americans and Europeans die each year from sudden cardiac death (SCD), which
causes 10–20% of all deaths among adults in the Western world (De VreedeSwagemakers et al., 1997; Zheng et al., 2001). Prevention and treatment of cardiac
arrhythmias include medical procedures such as cardioversion, implantable cardioverter
defibrillators (ICDs) and catheter ablation; surgical procedures such as coronary artery
bypass grafting; and the use of anti-arrhythmic medications. While some procedures
like radio-frequency ablation can cure arrhythmias (Morady, 1999), available antiarrhythmic drugs are incompletely effective in preventing arrhythmias, and such
treatment carries risks, including actually promoting arrhythmia (Knollmann & Roden,
2008). An understanding of the underlying mechanisms of arrhythmias is essential to
the future development of safe and effective preventative therapies.
The study of heart development and physiology in Drosophila melanogaster is
intensifying rapidly as it continues to expand as a model system for studying cardiac
problems generally and genetic influences in particular. Findings in the fly are directly
applicable to the human heart as a growing number of genes have been identified with
homologous function in both organisms (Bier & Bodmer, 2004). Drosophila
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melanogaster is the only insect in which the molecular genetic basis of heart
development process has been studied and reviewed in detail. Drosophila has an open
circulatory system consisting of a simple, linear, tubular heart that circulates hemolymph
through the larval and adult body cavity (Rizki, 1978). The transport of oxygen in the
fruit fly is carried out by their highly branched tracheal system. In stark contrast, the
vertebrate heart consists of an elaborate, closed system of chambers and vessels that
transport blood through the body of the organism in order to provide oxygen to the
tissues. Although the final heart structure in Drosophila is very different from that of
vertebrates, many of the basic elements for cardiac specification and differentiation are
conserved. The molecular components and basic control mechanisms of how the heart
develops and how it functions are strikingly similar in vertebrates, other chordates, and
insects (Bodmer, 1995; Bodmer & Venkatesh, 1998; Cripps & Olson, 2002; Harvey,
1996; Holland et al., 2003; Zaffran & Frasch, 2002).

(See Section I Introduction for

more detail about Drosophila melanogaster heart development.)
Melatonin (N-acetyl-5-methoxytryptamine), the main product of the pineal
gland, is well known for its regulation of the biorhythms. Since the identification of
melatonin by Lerner et al. (1958), it has been shown that melatonin is involved in the
regulation of many physiological systems, including the cardiovascular system (Vazan
et al., 2003;2005). Melatonin effects its response by either binding to one of its three
receptors (MT1, MT2 or MT3), binding to nuclear receptors, or through its antioxidant
activity. Very little research has been done attesting to melatonin’s effects on heart
arrhythmias. Only two studies have shown a relationship between melatonin and
reduced heart arrhythmia in rats (Bertuglia & Reiter, 2007; Benova et al., 2015). The
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former attributed melatonin’s anti-arrhythmic effects to its acute effects on myocardial
Cx43 channel’s mediated electrical coupling via Cx43 phosphorylation; the latter
attributed melatonin’s anti-arrhythmic effects to its ability to prevent tissue damage after
ischemia-reperfusion injury due to its powerful antioxidant activity. (See Section I
Introduction for more detail on melatonin.)

In this study, I examined the effects of melatonin and serotonin on heart rate
(frequency) and rhythmicity of Drosophila melanogaster wild-type and heart mutants
when injected into early (P1) pupae. If melatonin is exerting its anti-arrhythmic effects
via antioxidant mediated activity, it is expected that injection with serotonin will
produce similar results, owing to its equally powerful antioxidant properties. The
selected heart mutants (slowpoke, ether-a-go-go, no action potentialtemperature sensitive,
dunce, sarco-endoplasmic reticulum Ca2+-ATPase allele 170) were chosen based on
their arrhythmic phenotypes. (See Section I Introduction for a more detailed description
of the aforementioned Drosophila mutants.)

Based on a smaller scale study previously performed in our lab, I predicted
melatonin would increase heart rhythmicity without altering heart rate in Drosophila
wild type flies and some Drosophila heart mutants. The following experiments were an
attempt to elucidate the mechanism by which melatonin might be exerting its antiarrhythmic effects by observing the responses of the different heart mutants. Previous
experiments with Drosophila melanogaster have shown the acceleratory effects of
injected neurotransmitters such as serotonin, octopamine, norepinephrine, and
acetylcholine (Johnson et al., 1997), but there have been no published or reported
experiments carried out with melatonin thus far.
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Materials and Methods

Fly Cultures and Strains
All mutant and control strains were maintained in 250ml bottles in a 12:12 light:
dark (L:D) cycle under uncrowded conditions in a humidified, temperature-controlled
incubator at 25º on malt-molasses-cornmeal-agar medium. No population bottlenecks
occurred. Propionic acid was added to the medium to control mold growth (Jennings et
al. 2009).
Genetics
Homozygous individuals of the following Drosophila melanogaster strains were tested:
Canton-S (CS) wild-type
dunce (dnc1) (Dudai et al., 1976)
ether-a-go-go (eag) (Wu et al., 1983; Drysdale et al., 1991; Brüggemann et al., 1993)
no action potential temperature sensitive (napts) (Wu et al., 1978)
sarco-endoplasmic reticulum Ca2+-ATPase allele 170 (Ca-P60AKum170)
(Sanyal et al., 2005)
slowpoke (slo) (Elkins et al. 1986)

Reciprocal crosses were carried out with the mutant strain slowpoke and df [slo]
(slowpoke deficiency). Crosses with deficiency stocks lead to deletions which provide
definitive null alleles for the genes they uncover and are used to gauge the severity of
any particular allele; indeed, the classical test for defining an amorphic or null allele is to
assess whether the homozygous phenotype is as severe as when the allele is hemizygous
with a deletion (Roote & Russell, 2012). One cross contained 10 slowpoke virgin
females and 10 df [slo] males. The second cross contained 10 df [slo] virgin females and
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10 slowpoke males. Reciprocal crosses were maintained in 250ml bottles under the
same environmental conditions described above.
Ribonucleic Acid Interference (RNAi) is a process that permits elimination of
expression of targeted gene sequences in an attempt to understand their function (Bellés
2010). Ten slo RNAi virgin females were crossed with 10 GMH5-Gal4 males in order
to eliminate slo and mimic the slo mutation phenotype. This cross was maintained in a
250 ml bottle under the same environmental conditions described above. The heartspecific driver employed here is GMH5–Gal4, a 900-bp heart enhancer fragment 73
from the tinman gene (Bodmer, 1993; Venkatesh et al., 2000) that was cloned into the
P{GaWB} vector upstream of the Gal4 sequences. This driver was enhanced with
multiple copies of a UAS–Gal4 element allowing stronger myocardial expression when
activated in late embryonic or during adult stages (Wessells & Bodmer, 2004).
Measurement of Heartbeat
All test subjects were collected at the third-instar larval stage just as they were
entering the early pupal (P1) stage. At this point, they are translucent, making any heart
movements transmitted to the surrounding organs easily visible. Each pupa was placed
on a glass slide in a drop of distilled water and set in the light beam of an Olympus
binocular microscope. The light source was powered by a DC supply to eliminate 60 Hz
variation. The water served to stabilize and equilibrate temperature between the slide
and the pupa, as well as to increase the brilliance of the illumination passing through the
pupa. The pupa was adjusted so that one clear portion of the abdomen filled the field of
view with just the surrounding fat bodies visible. The movement of these organs results
in a variation in illumination that can be detected by a phototransistor. This signal is
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amplified and recorded in a microcomputer through a DAS8 AD converter (Johnson et
al., 1997). Temperature of the slide was maintained at 25 ̊ C with a Sensortek TS-4 unit,
however it was not possible to record temperatures within the animals. Recordings
were done for 10 minutes pre-injection and again post-injection. Over the 10-minute
time period for both pre-and post-injection recordings, heart frequency and heart
rhythmicity data were recorded at 1-minute intervals, resulting in 10 separate readings.
This allowed for analysis of the effects of injected substances over time. For preinjection recordings each pupa was allowed 1.5 minutes to equilibrate to 25 ̊ C after
being placed under the microscope and before recording started. After injection of a
substance, flies were immediately placed under the microscope and recording was
started without the 1.5 minute equilibration time in order to observe the immediate
effects of the injected substance.
Test of Ca-P60AKum170 mutant strain specifics
Both pre and post injection heartbeat were recorded for 10 minutes at 25 ̊ C for
the Ca-P60AKum170 mutant strains. In addition to the protocol for the other subjects, CaP60AKum170 mutants were also exposed to a 2.5 minute heat shock at 41 ̊ C either before
or after melatonin injection; in between pre- and post-injection heartbeat recordings.
For pre-injection heat shock, each pupa was placed in a glass vial and then
submerged in a 41 ̊ C water bath for 2.5 minutes. The pupa was then immediately
transferred to a glass slide, injected with melatonin and placed under the microscope for
post-injection recording. For post-injection heat shock, each pupa was first injected,
then immediately placed in a glass vial and subjected to the 41 ̊ C water bath for 2.5
minutes. The pupa was subsequently transferred to a glass slide and immediately placed
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under the microscope for post injection recording. Post-injection pupae were not
allowed any time to acclimate before recording to allow observation of any immediate
effects that injected substances might have.
Pharmacology of melatonin and ascorbic acid
Melatonin is insoluble in water and must initially be dissolved in ethyl alcohol.
For consistency, both melatonin and ascorbic acid were first dissolved in 1 % ethyl
alcohol and then added to Calcium-free Drosophila Ringer’s solution (Ashburner,
1989). Concentrations of 2500 µM, 1000 µM, 500 µM, 100 µM, and 50 µM melatonin
were prepared to assay dose response. A single concentration of 1000 µM ascorbic acid
was prepared. Based on these results, the standard concentration used for ensuing
experiments of both melatonin and ascorbic acid injections was 1000 µM.
Solutions were perfused directly over the pacemaker and caudal region of the
dorsal vessel by injection into the caudal end of the animal (Johnson et al., 1997). Glass
electrodes were used for injection and were pulled on a World Precision Instrument
PUL-100 micropipette puller. Tips were gently broken to assure sharpness.
Following a 10 minute pre injection recording, the pupa was placed under an
Olympus dissecting scope for injection. A World Precision Instrument Nanoliter
Injector (model # A203XVY) was calibrated to administer 46 nl volume of liquid. A
micromanipulator was used to position the glass electrode in the dorsal posterior region
near the caudal region of the heart. Heartbeat was recorded for 10 minutes before
injection and for 10 minutes immediately (within 1 minute) after injection of a substance
as delineated above.
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Analysis of heartbeat data
Data from individual flies taken at 25 ̊ C were analyzed by autocorrelation
(Chatfield, 1980) and Maximum Entropy Spectral Analysis (MESA) (Ulrych & Bishop,
1975; Dowse, 1989; Levine et al., 2002; Dowse, 2009). Estimations of heart rate
frequency were based both on the spectral analysis and on inspection of the raw data
plots and autocorrelation for verification.
Regularity of the heartbeat was quantified from the autocorrelation analyses.
Rhythmicity in the signal results in recurring peaks of positive and negative correlation
and the decay envelope reflects regularity in the signal (Chatfield, 1980). The height of
the second peak was expressed as a fraction of the height of the zeroth lag, (i.e., a
coefficient of correlation; see Dowse et al., 1995; Levine et al., 2002; Dowse, 2009 for
details). We refer to this coefficient as “rhythmicity (RI).” We commonly observe that
with more skipped beats, irregular intervals between beats, periods of heartbeat
cessation, and rate variations tracks the level of irregularity in RI (Johnson, Ringo, &
Dowse, 2000; Levine et al., 2002; Dowse, 2009).
The program was set up to measure heart rate frequency and heart rhythmicity
over a 10 minute period. At each minute over the 10 minute period, a value for
frequency and rhythmicity was calculated. This program allows us to examine the
effects of injected substances over a longer period of time allowing estimates of when
the effects began and how long they last (see figure 1.1).
In order to further explore the way in which the heartbeat was altered by the
injection of melatonin, we wrote software to sort through the recorded data to pinpoint
and record the duration of the interval between each peak in the signal and the next.
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Intervals in which the signal equaled or exceeded the mean of the absolute value of the
time series were identified sequentially and a simple bubble sort was applied to identify
the highest value in this time frame. Its time was recorded. Thus we are able to
visualize the “Inter-Beat Interval” or IBI as a function of time. Fig 1.1g-j shows an
example of this analysis, the IBI for a Canton-S pupa recorded for 10 minutes and
plotted as a function of time.
Because each fly was used as its own control and more than two measurements
were carried out on the same subject Repeated Measures Analysis of Variance
(ANOVA) tests were used to compare data before injection and after injection for each
Drosophila strain tested. Kolmogorov-Smirnov goodness of fit tests were used to show
that all data were normally distributed. Both tests were carried out within the statistical
software R.
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Results
Data Analysis Figures
Figure 1.1 Full analysis of the heartbeat of a CS pupa before and after injection
with 1000μM melatonin. a, b Raw data optical recording: a 30-s segment starting at the
midpoint of the raw data before (a) and after (b) melatonin injection shows this
difference in more detail. This 30-s segment is representative of the 4 minute segments
indicated in (k). c, d Autocorrelation for these segments used to assess regularity of
heart rhythm before (c) and after (d) melatonin injection. e, f Spectral analysis (MESA)
for heart rate (frequency) of these segments starting at the midpoint before (e) and after
(f) melatonin injection. g, h Interbeat Interval (IBI) analysis shows this change in a
more objective fashion. (g) (before) and (h) (after) show the IBI analyses for both
records in their entirety. The change in regularity is easily seen after a period of “wash
in”. Note the development of the more regular beat after the wash-in period. i, j 30-s
segments starting at the midpoint of the data show the IBI analysis at higher
magnification before (i) and after (j) injection. The difference in the variability of IBI is
striking. Autocorrelation and MESA for these segments (c) and (d) and (e) and (f) are
remarkable and clearly track the change in IBI. Together, these analyses point towards
the increase in RI stemming from the change in variance in IBI. (k) Shows the average
(CS pupae, N=30) rhythmicity index (RI) for each minute; 10 minutes before injection
and 10 minutes after injection. The horizontal bar over minutes 4-7 and 15-18 indicate
time segments used for comparison in all experiments.
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a. Raw data optical recording: a 30-s segment starting at the midpoint of the raw data
before melatonin injection

b. Raw data optical recording: a 30-s segment starting at the midpoint of the raw data
after melatonin injection
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c. Autocorrelation used to assess regularity of heart rhythmn before melatonin injection

d. Autocorrelation used to assess regularity of heart rhythmn after melatonin injection
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e. Spectral analysis (MESA) for heart rate (frequency) of these segments starting at the
midpoint before melatonin injection

f. Spectral analysis (MESA) for heart rate (frequency) of these segments starting at the
midpoint after melatonin injection
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g. Interbeat Interval (IBI) analysis of entire 10 minute recording before melatonin
injection

h. Interbeat Interval (IBI) analysis of entire 10 minute recording after melatonin
injection
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i. IBI analysis at higher magnification; 30-s segment starting at the midpoint before
melatonin injection

j. IBI analysis at higher magnification; 30-s segment starting at the midpoint before
melatonin injection
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k. Shows the average (CS pupae, N=30) rhythmicity index (RI) for each minute; 10
minutes before injection and 10 minutes after injection
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Dose response of injected melatonin in wild type and slowpoke pupae
Both wild type and slowpoke pupae were injected with 50, 100, 500, 1000 and
2500 µM concentrations of melatonin. Wild-type (Canton-S) pupae showed significant
increase in heart rhythmicity with injections of 500, 1000 and 2500 µM melatonin with
% increase in heart rhythmicity of 32 %, 47 % and 39% respectively (p < 0.05) as
compared to rhythmicity before melatonin injection. Melatonin injections of 0 µM
(control injections of Ca+2 free ringers and Ca+2 free ringers with 1% ethanol), 50 µM
and 100 µM in wild type pupae showed no significant change in heart rhythmicity
(p > 0.05) (Figure 1.2). Slowpoke (slo) pupae showed significant increase in heart
rhythmicity with injections of 100, 500, 1000 and 2500 µM melatonin with
% increase in heart rhythmicity of 19 %, 77%, 98% and 40% respectively (p < 0.05).
Melatonin injections of 0 µM (control injections of Ca+2 free ringers and Ca+2 free
ringers with 1% ethanol), and 50 µM slo pupae showed no significant change in heart
rhythmicity (p > 0.05) (Figure 1.3). There was no significant change in heart rate in
either wild type or slo pupae across all injected concentrations of melatonin (p > 0.05).
The peak response for both wild type and slo pupae was with injection of 1000 µM
melatonin. This was chosen as the standard dose used in all experiments.
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Figure 1.2 Canton-S melatonin dose response curve

Figure 1.3 Slowpoke melatonin dose response curve
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Effects of melatonin on heart rate and rhythmicity of Drosophila melanogaster
wild- type and heart mutant pupae
Both wild type and heart mutant pupae injected with 1000 µM melatonin showed
significant increase in heart rhythmicity ranging from 54 to 104% (Table 1.1 and Fig
1.4). Canton S, eag, slo, napts, and slo x df [slo]d pupae showed a significant decrease
in heart rate ranging from 2 to 12 % (p < .05), but all other strains showed no significant
change in heart rate (Table 1.2 and Fig. 1.5).
Control pupae were injected with Drosophila calcium free ringers solution or
calcium free ringers solution with 1% ethanol. Controls showed no significant change in
heart rhythmicity or in heart rate (p > 0.05).
Due to the initial period of time that it took for melatonin to exert its effects,
minutes 4 through 7 were chosen as significant values for calculation of the means taken
pre and post injection for both heart rate and rhythmicity. This protocol was used across
all measurements except those involving a heat shock protocol (see fig. 1.1k).
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Table 1.1 Effects of melatonin injection on heart rhythmicity in wild-type and heart mutants

Genotype

Meltonin
Injected
µmol-1a

Mean
RI
Preb
25´C

Mean
RI
Postc
25´C

%
Change

Canton-S (+)

1000

0.449

0.694

+54%

30

0.02/0.02

(1,29) 158.7

dnc1

1000

0.404

0.702

+74%

10

0.04/0.04

(1,9) 86.4

2.00e-13 ***

eag

1000

0.287

0.584

+104%

5

0.04/0.04

(1,4) 120.7

1.16e-11 ***

napts

1000

0.406

0.746

+84%

30

0.02/0.01

(1,29) 338.6

< 2e-16 ***

slo

1000

0.357

0.681

+91%

42

0.02/0.01

(1,41) 61.4

9.29e-14 ***

slo x df [slo] d

1000

0.418

0.733

+76%

20

0.02/0.02

(1,19) 341.6

< 2e-16 ***

df [slo] x sloe

1000

0.379

0.711

+87%

11

0.02/0.02

(1,10) 292.1

<2e-16 ***

sloRNAi x GMH5f

1000

0.305

0.570

+87%

5

0.03/0.02

(1,4) 86.1

a

+/- SEM
Pre/Post

F Value

P Value
<2e-16 ***

4.89e-10 ***

Concentration of melatonin injected

b
c

N

Mean Rhythmicity Index pre-injection minutes 4-7

Mean Rhythmicity Index post-injection minutes 4-7

d

slo virgin females crossed with df [slo] males

e

df [slo] virgin females crossed with slo males

f

sloRNAi virgin females crossed with GMH5-Gal4 males

*** p < 0.001 comparing before injection to after melatonin injection within each strain
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Figure 1.4 Effects of 1000 µM melatonin injection on wild-type and heart mutants
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Table 1.2 Effects of melatonin injection on heart rate in wild-type and heart mutants

Genotype

Meltonin
Injected
µmol-1a

Canton-S (+)

1000

Mean
Heart
Rate
Preb
25´C
2.28

dnc1

1000

2.04

eag

1000

napts

Mean
Heart
Rate
Postc
25´C
2.21

%
Change

N

-3%

1.98

1.89

1000

slo

+/-SEM
Pre/Post

F Value

P Value

30

0.02/0.03

(1,29) 6.1

0.0144 *

- 3%

10

0.03/0.04

(1,9) 1.3

0.251

1.80

- 5%

5

0.03/0.04

(1,4) 5.4

0.027 *

2.29

2.01

- 12%

30

0.05/0.05

(1,29) 19.1

4.69e-05 ***

1000

2.37

2.28

- 4%

42

0.02/0.02

(1,41) 14.7

0.00015 ***

slo x df [slo]d

1000

2.46

2.41

- 2%

20

0.04/0.04

(1,19) 5.7

0.0199 *

df [slo] x sloe

1000

2.16

2.12

- 2%

11

0.05/0.04

(1,10) 0.4

0.514

sloRNAi x
GMH5f

1000

1.81

1.72

- 5%

5

0.05/0.04

(1,4) 2.3

0.140

a

Concentration of melatonin injected

b
c

Mean heart rate pre-injection minutes 4-7

Mean heart rate post-injection minutes 4-7

d

slo virgin females crossed with df [slo] males

e

df [slo] virgin females crossed with slo males

f

sloRNAi virgin females crossed with GMH5-Gal4 males

* p < 0.05 comparing before injection to after melatonin injection within each strain
*** p < 0.001 comparing before injection to after melatonin injection within each strain
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Figure 1.5 Effects of melatonin injection on heart rate in wild-type and heart mutants
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Effects of melatonin injection on heart rhythmicity of Ca-P60AKum170 (SERCA 170)
mutants before and after 2.5 minute heat shock at 41 ̊ C
Both wild-type and SERCA170 pupae showed a significant decrease in heart
rhythmicity with 2.5 minute 41 ̊ C heat shock alone (F(1,4) = 153.6; p < 0.001 and
F(1,4) = 32.6;

p < 0.001). Injections of 1000 µM melatonin before and after heat

shock showed significant increase in heart rhythmicity in both wild-type and SERCA170
strains (Melatonin injection before heat shock: F(1,4) = 9.4; p < 0.05 and F(1,9) = 51.1;
p < 0.001; Melatonin injection after heat shock: F(1,4) = 30.1; p < 0.001 and F(1,9) =
28.0; p < 0.001). (Fig. 1.6 and 1.7).

For recording where melatonin was injection before the 2.5 minute heat shock,
minutes 1-10 of pre and post injection were compared and statistically analyzed. For
recordings where melatonin was injected after the 2.5 minute heat shock, minutes 7-10
of pre and post injection were compared and statistically analyzed.
Comparison of wild-type to SERCA 170 mutants showed a similar trend where
significant increase in heart rhythmicity occurred across the entire 10 minute recording
with melatonin injection before heat shock, while significant increase in heart
rhythmicity didn’t begin until minute 7 with melatonin injections after heat shock, and
continued to increase from that point (Fig. 1.8 and 1.9).

Control pupae were injected with Drosophila calcium free ringers solution with
1% ethanol. Controls showed no significant change in heart rhythmicity with injection
before or after 2.5 minute heat shock at 41 ̊ C (p > 0.05).
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Figure 1.6 Effects of 1000 µM melatonin injection on SERCA 170 pupae before and
after 2.5 minute heat shock

Figure 1.7 Effects of 1000 µM melatonin injection on Canton-S pupae before and after
2.5 minute heat shock
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Figure 1.8 Canton-S vs. SERCA 170 1000 µM melatonin injection after 2.5 minute heat
shock

Figure 1.9 Canton-S vs. SERCA 170 1000 µM melatonin injection before 2.5 minute
heat shock
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Effects of Serotonin on heart rate and rhythmicity of wild type and slowpoke
mutants
Injection of 1000 µM serotonin in both wild-type and slowpoke pupae had no
significant effect on heart rhythmicity (p > 0.05) (Table 1.9 and Fig 1.10).
Injections of 1000 µM serotonin did significantly increase heart rate in both
wild-type and slowpoke pupae ranging from 28 to 31 % (p < 0.001) (Table 1.10 and Fig
1.11).
Results of serotonin injection are opposite of results of melatonin injection
whereby melatonin increases heart rhythmicity without increasing heart rate, serotonin
increases heart rate without increasing heart rhythmicity.
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Table 1.3 Effects of 1000 µM serotonin injection on heart rhythmicity in wild-type and
slowpoke pupae

Genotype
Canton-S
(+)
slowpoke

a

Mean
RI
Pre
25´C

Mean
RI
Post
25´C

%
Change

1000

0.543

0.585

1000

0.190

0.211

N

+/- SEM
Pre/Post

F Value

P Value

+7%

5

0.04/0.03

(1,4) 2.2

0.150

+11%

5

0.03/0.03

(1,4) 0.2

0.671

Concentration of serotonin injected

b
c

Serotonin
Injected
µmol-1a

Mean Rhythmicity Index pre-injection minutes 4-7

Mean Rhythmicity Index post-injection minutes 4-7

Figure 1.10 Effects of 1000 µM serotonin injection on heart rhythmicity in wild-type
and slowpoke pupae
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Table 1.4 Effects of 1000 µM serotonin injection on heart rate in wild-type and
slowpoke pupae

Genotype

Canton-S
(+)
slowpoke

a

1000

Mean
Heart
Rate
Pre
25´C
2.37

Mean
Heart
Rate
Post
25´C
3.11

1000

2.27

2.91

%
Change

N

+/-SEM
Pre/Post

F Value

P Value

+ 31%

5

0.06/0.05

(1,4) 35.7

1.98e-06 ***

+ 28%

5

0.04/0.04

(1,4) 473.1

< 2.2e-16 ***

Concentration of serotonin injected

b
c

Serotonin
Injected
µmol-1a

Mean heart rate pre-injection minutes 4-7

Mean heart rate minutes 4-7

*** p < 0.001 comparing before injection to after serotonin injection within each strain

Figure 1.11 Effects of 1000 µM serotonin injection on heart rate in wild-type and
slowpoke pupae
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Discussion
Heart rhythmicity in Drosophila melanogaster is remarkably and consistently
increased by injection of melatonin in wild type pupae (P1) and pupae exhibiting a
variety of heart mutations. Percentage increase in heart rhythmicity ranged from 54% in
wild-type to 104% in eag progeny. Curiously, melatonin significantly increased heart
rate by 7% in eag, but did result in a significant decrease in heart rate in Canton S, slo,
eag, napts, and slo x df [slo]d pupae. Data from injections with serotonin, melatonin’s
precursor, also supported the previous findings of Johnson et al., 1997, that serotonin
significantly increases heart rate in wild-type and slo pupae by 31% and 28%
respectively without significantly affecting heart rhythmicity.
Both melatonin and serotonin exhibit powerful antioxidant properties owing to
their ability to scavenge damaging free radicals produced by reactive oxygen species
(ROSs) (Bonilla et al., 2006; Gülçin, 2008; Oxenkrug, 2005; Gitto et al., 2001; Head,
2005; Pieri et al., 1994). Serotonin was found to have higher DMPD (N, N–dimethyl-pphenylendiamine) radical scavenging and cupric ions (Cu2+) reducing activity than
melatonin because of its phenolic group (Gülçin, 2008). While several studies in
vertebrates have attributed melatonin’s cardio protective properties to its antioxidant
activity (Reviews: Reiter & Tan, 2003; Tengattini et al., 2007), serotonin has not been
utilized in such experiments because, unlike melatonin, it also increases heart rate. It is
also important to note that studies showing anti-arrhythmic effects of melatonin in
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hamsters and rats were in conjunction with oxidative stress caused by ischemiareperfusion damage. Melatonin was able to reduce oxidative stress caused by ischemiareperfusion injury, and thereby reduce the incidence of post-ischemic-reperfusion
induced ventricular tachycardia (VT) and ventricular fibrillation (VF) (Bertuglia &
Reiter, 2007).
The experiments carried out in this study report on the immediate antiarrhythmic effects of melatonin when injected directly over the dorsal vessel and
pacemaker of Drosophila pupae with no oxidative stress incurred by the animal. Also, if
melatonin’s anti-arrhythmic effects are owing to its antioxidant properties, one would
expect serotonin to have similar anti-arrhythmic effects, which is not the case.
In support of melatonin’s anti-arrhythmic effects being receptor mediated and
not antioxidant mediated, I designed experiments to inject concentrations of ascorbic
acid (vitamin C) into Drosophila pupae. Results of ascorbic acid injections showed a
5% and 24% decrease in heart rhythmicity in wild type and slo pupae, respectively
(See Chapter 2 Results).
Based on the above results and discussion and results of ascorbic acid
experiments in chapter 2 of this manuscript, I believe that it is highly unlikely that
melatonin’s anti-arrhythmic effects in Drosophila melanogaster are antioxidant
mediated. Instead, I hypothesize that melatonin produces these effects by binding to a
melatonin receptor and initiating a signaling pathway of events that ultimately lead to
increased heart rhythmicity.
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While this hypothesis is well supported by the experiments performed in this
study and experiments carried out in Chapter 2 of this manuscript, outside speculation
regarding melatonin’s ability to modulate heart rhythmicity through receptor binding is
limited and somewhat ambiguous. Since heart rate and rhythmicity in vertebrates and
Drosophila are both primarily regulated by pacemaker activity, it makes sense to turn
our attention to possible direct effects of melatonin on pacemaking. The pacemaker in
both organisms comprises an ensemble of ion channels. The underlying biophysics of
the oscillatory behavior may vary in detail, but the overall similarities are striking and
insect research has already carried over into understanding vertebrate mechanisms with
implications for human health (Bodmer et al., 2005).
Pacemaking in these organisms is dependent on Ca+2 and K+ ion currents but not
dependent on Na+ (Irisawa et al., 1993; McCann & Sanger, 1969; McCann, 1963, 1969;
Miller, 1985). Many of the heart mutants that I chose to test in these experiments have
altered heart rate and/or heart rhythms due to mutations in genes that encode both Ca+2
and K+ ion channels and calcium signaling pathways involved in pacemaker function of
the heart. Human homologues of these genes have also been identified (see
Introduction). As mentioned above, heart rhythmicity is increased with injection of
melatonin in wild type and all heart mutants tested. There does appear to be a positive
correlation between percentage increase in heart rhythmicity and the potassium channel
mutations ether-a-go-go and slowpoke with heart rhythmicity increase ranging from 91104%, which would indicate that melatonin may be directly affecting K+ ion channels in
a way that mitigates the effect of the mutated channel.
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I also tested a mutation that affects the level of sodium channel activity and, at
high temperature, causes paralysis associated with a loss of action potentials. napts is a
gain-of-function allele of maleless (mle), a gene required for X chromosome dosage
compensation and male viability (Kernan et. al, 1991). napts slows heartbeat and renders
it less rhythmic and prevents the heart from responding to temperature with an altered
rate (Dowse et al., 1995). It has also been shown that even at permissive temperature,
napts suppresses the effects of a variety of mutations (Shaker, ether-a-go-go,
Hyperkinetic) that affect potassium channels and cause increased membrane excitability
(Ganetzky & Wu, 1982). Melatonin did increase heart rhythmicity in napts mutants by
84%. Even though pacemaking in both vertebrates and invertebrates has been shown to
be independent of Na+ ion currents, it is possible that this gain-of-function allele may be
exerting its effects on the heart by interacting with potassium and/or calcium ion
channels in the Drosophila pacemaker.
The other two mutations that I tested were not specific mutations of calcium
channels, but rather were ones that affect calcium transport into the sarcoplasmic
reticulum (Ca-P60AKum170) and the calcium-calmodulin signaling pathway via
interactions with a cAMP-specific phosophodiesterase encoded by dnc1.
Ca-P60AKum170 is an EMS-induced mutant that affects sarco-endoplasmic
reticulum calcium ATPase (SERCA), a membrane protein that pumps free cytosolic
calcium into intracellular stores. Abnormalities in the amount or structure of the
SERCA protein have been linked to cardiac malfunction in mammals. One of the most
consistently observed abnormalities in patients with ventricular arrhythmias is the
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impaired ability to handle intracellular calcium due to changes in ryanodine receptor
(RyR) and sarco-endoplasmic reticulum Ca2+ - ATPase (SERCA) (Wolk, 2000).
This Drosophila SERCA mutant shows a severe decrease in heart rhythmicity
after being subjected to a 2.5 minute heat shock at 41̊ C (Sanyal et al., 2006). When
these pupae were injected with melatonin before heat shock, they showed an increase in
heart rhythmicity of 137%. When these pupae were injected with melatonin after heat
shock, they showed an increase in heart rhythmicity of 123%. I attribute the difference
in the results between the two protocols to the fact that melatonin had a longer time to
exert its effects when injected before heat shocking as wild type flies subjected to the
same protocols showed a similar trend (170% increase before and 158% after). Based
on these results and previous experiments indicating the importance of SERCA and RyR
in regulating intracellular calcium levels of myocardial cells and maintenance of heart
rhythmicity, melatonin may have an effect on intracellular calcium levels through
another pathway or may be affecting ryanodine receptors indirectly. Experiments with
Drosophila ryanodine receptor mutants were not performed in this study, but would be
of interest in the investigation of melatonin’s effects in future experiments.
Results in this study showed only a 74% increase in heart rhythmicity in dnc1
mutants. The mutation dunce (dnc1), encodes a cAMP-specific phosphodiesterase
(PDE), which interacts with the calcium-calmodulin signaling pathway (Walter & Kiger,
1984). Turjanski et al., 2004, found that melatonin can modulate this signaling pathway
by changing the concentration of intracellular calcium via activation of its G proteincoupled receptors. It is possible that melatonin is exerting its anti-arrhythmic effects
through this signaling pathway, but no conclusion can be drawn from this result.
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Recent research has reported that long term administration of melatonin to
ventricular fibrillation (VF)-prone spontaneously hypertensive (SHR) and normotensive
Wistar rats confers protection from lethal arrhythmia because of the increase in the VF
threshold. The antiarrhythmic effect of melatonin was associated with the enhancement
of myocardial Connexin 43 (Cx43) gene expression as well as the total levels of Cx43
protein and its functional phosphorylated forms in both SHR and Wistar rat hearts
(Benova et al., 2013, 2015). In addition to these findings, Ai et al. 2000, found that
Wnt-1 is a specific and potent inducer of Cx43 expression in cardiomyocytes and that
this effect results in enhanced accumulation of Cx43 protein and formation of functional
gap junction channels. Interestingly, the gene product of wingless (wg), the Drosophila
Wnt homologue, has been shown to be crucial for normal heart development, where it
appears to be absolutely required for specifying the heart progenitors (Park et al., 1996,
1998). It is also known that mononucleate cardiomyocytes that comprise the heart tube
in invertebrates such as Drosophila are electrically connected by gap junctions formed
by innexin (Connexin is the vertebrae homologue). Perhaps melatonin is having a
similar effect on the innexins in the Drosophila heart.
Although it is highly likely that melatonin is producing its anti-arrhythmic
effects by binding to a melatonin receptor, the possible mechanisms that affect
rhythmicity are diverse and complex. Future research should first focus on positive
identification and characterization of a melatonin receptor in Drosophila (See Chapter
2). Melatonin’s anti-arrhythmic pathway would be open to further study were such a
receptor to be identified and characterized.
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CHAPTER 2
ANALYSIS OF MELATONIN ACTION AND POSSIBLE IDENTIFICATION OF
A MELATONIN RECEPTOR IN Drosophila melanogaster
Abstract
Melatonin injection into P1 pupae of Drosophila melanogaster results in an
acute and profoundly significant increase in heart rhythmicity ranging from 47-151%
without altering heart rate of the organism. In the present study luzindole, a noncompetitive melatonin antagonist; 2-iodomelatonin, a high affinity melatonin agonist;
and ascorbic acid, a powerful antioxidant are injected into Drosophila wild-type and
heart mutant pupae in order to investigate melatonin’s anti-arrhythmic mechanisms.
Animals injected with luzindole and melatonin showed no significant increase in heart
rhythmicity in wild type or heart mutant pupae showing that luzindole was able to block
melatonin’s anti-arrhythmic effects. Animals injected with 2-iodomelatonin showed an
11 % and 15 % greater increase in heart rhythmicity than melatonin in wild type and
slowpoke (slo). Wild type and slo pupae injected with ascorbic acid showed a
significant decrease in heart rhythmicity. Results from all three injected substances
provide strong support for the hypothesis that melatonin’s anti-arrhythmic effects are
receptor mediated as opposed to antioxidant mediated. On the basis of these findings, an
attempt to identify a possible melatonin receptor in Drosophila melanogaster was made
by using RNA interference (RNAi) and loss of function tests with four different
Drosophila orphan G protein-coupled receptors (CG4313, CG3171, CG13579,
CG13575). While CG3171, CG13579, and CG13575 showed no loss of function (i.e.
heart rhythmicity still increased with melatonin injection by 27 %, 26 % and 33 %
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respectively), CG4313 exhibited loss of function (no significant increase in heart
rhythmicity with melatonin injection). This finding indicates that the CG4313 orphan
receptor may be a melatonin receptor in Drosophila melanogaster.
Introduction
Melatonin (N-acetyl-5-methoxytryptamine), an indolamine which is biologically
synthesized from the amino acid L-Tryptophan, is the methoxy derivative of serotonin.
The discovered molecule was named melatonin because of its effects on melanin
(‘mela-’) aggregation in the melanocytes of amphibians (Lerner et al., 1958) and its
derivation from serotonin (‘-tonin’). Melatonin is present in the earliest life forms and is
found in all organisms including bacteria, algae, fungi, plants, insects, and vertebrates
including humans (Tan et al., 2003). Although melatonin is typically referred to as a
hormone, the diversity of actions that it effects do not always comply with the
conventional definition of a hormone. A hormone is defined as a molecule that is
synthesized in an organ, released into a bodily fluid (usually the bloodstream) from
where it travels to another cell or group of cells were it acts via specific receptors to
mediate its effects. Many of melatonin’s affects are not receptor mediated. It is well
known that melatonin is a potent antioxidant, even more powerful than vitamin E (Pieri
et al., 1994). The ability of melatonin and its metabolites to expunge free radicals and
related reactants possibly involves all of the following actions: a) direct detoxification of
radicals and radical products, b) stimulation of the activities of several antioxidative
enzymes, c) inhibition of the activities of pro-oxidative enzymes, d) promotion of the
synthesis of glutathione, another essential antioxidant, e) synergistic actions with other
antioxidants, and f) mitochondrial actions of melatonin that reduce free radical
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generation (Reiter et al., 2007). Melatonin also acts as an autocoid when it is released
by a cell and acts on another cell in the immediate vicinity (Tan et al., 2003). In
mammals, melatonin can also signal intracellular processes via activation of two highaffinity G-protein-coupled receptors designated MT1 and MT2 (Dubocovich et al.,
1983; Dubocovich & Markowska, 2005; Reppert et al., 1996). See Introduction for
more detail on melatonin receptors.
Often in preliminary experiments with melatonin, it is unknown whether its
observed effects are antioxidant or receptor mediated. This is especially true if
melatonin receptors have not yet been identified and characterized in the organism that
is being tested, as is the case with Drosophila melanogaster. Serotonin (5hydroxytryptamine; 5-HT) is a precursor to melatonin. Four receptors for 5-HT have
been described in Drosophila: one shares sequence homology to the vertebrate 5HT
receptor type 2 (5HT2R; CG1056), one is similar to the vertebrate serotonin receptor
type 7 (5HT7R; CG12073) and two show high homology to vertebrate 5HT1 type
receptor (5HT1AR and 5HT1BR; CG16720 and CG15113, respectively) (Silva et al.,
2014). Drosophila melanogaster synthesizes its own serotonin (Livingstone, 1981) and
also has several clusters of serotonergic neurons located in its central nervous system
(Valles, 1988).
Conversion of serotonin to N-acetylserotonin, the direct precursor of the
melatonin, is catalyzed by serotonin N-acetyltransferase (AANAT) in a reaction
requiring acetyl coenzyme A (AcCoA) (Hickman et al., 1999). Two different AANATs
(AANAT1 and AANAT2) have been identified and characterized in Drosophila
melanogaster (Hintermann & Meyer, 1995; Brodbeck et al., 1998; Amherd et al., 2000),
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but it is unknown whether Drosophila makes endogenous melatonin. Because
Drosophila and vertebrate serotonin receptors and vertebrate melatonin receptors all
belong to the G protein-coupled 7-transmembrane family, it is likely that if they exist,
melatonin receptors in Drosophila would also be of this type. Analysis of the completed
Drosophila genomic sequences (Brody & Cravchik, 2000; Adams et al., 2000) identified
>100 genes encoding G protein-coupled receptors (GPCRs). Further analysis indicated
that 44 such receptors are likely to have peptide ligands and that the majority of these
are derived from ancestors for mammalian peptide GPCR genes (Hewes & Taghert,
2001). At present, 35 peptide amine GPCRs are functionally characterized in
Drosophila. Another 14 GPCRs are predicted to be involved in neuropeptide signaling
pathways, but their ligands are still unknown and therefore they are classified as
“orphan” amine receptors (Caers et al., 2012).
The use of melatonin agonists and antagonists is a good first approach to
elucidating melatonin’s effects. Luzindole is a melatonin receptor antagonist for the
human MT1 and MT2 receptors (pKi 6.2-6.8 and pKi 7.6-8.1 respectively) (Dubocovich,
1988). Luzindole has been used in a number of experiments and acts by blocking
melatonin’s effects, which supports melatonin’s receptor mediated actions (Blask et al.,
2002; Dubocovich et al., 1998; Leja-Szpak et al., 2010; Rezzani et al., 2006; Roth et al.,
1999; Yu et al., 2014). 2-[125I]iodomelatonin is a selective, high-affinity ligand for the
identification and characterization of melatonin receptor sites. The binding affinity of 2[125I]iodomelatonin to human MT1 and MT2 receptors displays values of pKi 10.2-11.0
and pKi 9.7-10.3 respectively (Audinot et al., 2003). The specific binding of 2[1251]iodomelatonin fulfills all the criteria for binding to a receptor site, being stable,
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reversible, saturable, and of high affinity (Dubocovich & Takahashi, 1987). 2[125I]iodomelatonin binding acts by mimicking the effects of melatonin and has been
used to identify melatonin receptors in a variety of peripheral tissues in vertebrates
(Pang et al., 1993).
Another deorphanization tool is a loss-of-function approach called RNA
interference (RNAi). This allows us to eliminate targeted gene sequences in an attempt
to understand their function (Bellés, 2010). (See Section I Introduction for more details
on RNA interference.) Drosophila RNAi is cell-autonomous, and because of this,
targeted expression of RNAi constructs using the Gal4/UAS system (Brand & Perrimon,
1993) can be used for cell- or tissue-specific interrogation of gene function. Indeed, this
approach has been used extensively.
Typically, different Gal4-driver lines are crossed with UAS-target gene lines,
and the effects of tissue-specific gene expression are examined in the progeny. The
Gal4-UAS system provides a number of distinct advantages including promoter
expression patterns when using UAS-β-galactosidase (UAS-lacZ) or UAS-green
fluorescent protein (GFP) as a tissue marker; ectopic expression in a variety of tissues,
and the tissue-specific effects of specific gene knockdown using UAS-RNAi lines
(Dietzl et al., 2007; Haley et al., 2009). For example, tinC-GAL4 or GMH5-Gal4 can be
used to drive cardiac-specific transgenes to express recombinant cDNA to examine
ectopic protein expression or RNAi to examine specific gene knockdown in the heart
(Neely et al., 2010; Taghli-Lamallem et al., 2008). Although these drivers do capture
the heart it is important to note that they may also include other sites of expression in the
animal.
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The goals of the experiments carried out in this study are twofold: 1. To clarify
whether melatonin’s anti-arrhythmic effect (shown in Chapter 1) are antioxidant or
receptor mediated 2. To identify a specific melatonin receptor in Drosophila
melanogaster.
The first group of experiments examining melatonin’s antioxidant vs. receptor
mediated effects involved a series of co-injections of luzindole antagonist and melatonin
into Drosophila early pupae (P1), and a second series of injections of high affinity
agonist 2-[125I]iodomelatonin or ascorbic acid (vitamin C). The second group of
experiments attempted to implicate a Drosophila orphan receptor using paired specific
receptor RNAi strains crossed with the GMH5-Gal4 heart specific driver and then
injecting melatonin. A knock-down of the orphan receptor combined with loss-offunction with melatonin injection (no increased heart rhythmicity) would implicate a
melatonin receptor
Materials and Methods
Fly Cultures and Strains
All mutant and control strains were maintained in 250ml bottles in a 12:12 light:
dark (L:D) cycle under uncrowded conditions in a humidified, temperature-controlled
incubator at 25º Con malt-molasses-cornmeal-agar medium. No population bottlenecks
occurred. Propionic acid was added to the medium to control mold growth (Jennings et
al., 2009).
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Genetics
Homozygous individuals of the following Drosophila melanogaster strains were tested:
Canton-S (CS) wild-type
no action potential temperature sensitive (napts) (Wu et al., 1978)
slowpoke (slo) (Elkins et al., 1986)

RNAi strains and crosses
The heart-specific driver employed here is GMH5–Gal4, a 900-bp heart
enhancer fragment 73 from the tinman gene (Bodmer 1993; Venkatesh et al., 2000) that
was cloned into the P{GaWB} vector upstream of the Gal4 sequences. This driver was
enhanced with multiple copies of a UAS–Gal4 element allowing stronger myocardial
expression when activated in late embryonic or during adult stages (Wessells & Bodmer,
2004).
RNAi strains of Drosophila melanogaster of G-protein coupled orphan receptors tested:
CG 4313 RNAi (FlyBase ID: FBgn0025632)
CG 3171 RNAi (FlyBase ID: FBgn0046687)
CG 13579 RNAi (FlyBase ID: FBgn0014445)
CG 13575 RNAi (FlyBase ID: FBgn0034996)
Ten virgin females of each RNAi strain were collected and crossed with ten
GMH5 males. In addition, a reciprocal cross of ten GMH5 virgin females and
ten CG4313 RNAi males was carried out based on the results of possible melatonin
receptor identification from the original CG4313 RNAi cross. Crosses were maintained
in 250ml bottles under the same environmental conditions described above.
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First generation (F1) pupae from these crosses were injected with 1000 µM
melatonin and heart rhythmicity and frequency were recorded. If melatonin injection
still caused an increase in rhythmicity, the silenced orphan receptor was eliminated. If
melatonin injection did not cause an increase in rhythmicity, the orphan receptor was
considered a candidate melatonin receptor.
Measurement of Heartbeat
See Materials & Methods, Chapter 1

Pharmacology of melatonin, luzindole and 2-[125I]iodomelatonin and L-ascorbic
acid
Melatonin is insoluble in water and must initially be dissolved in ethyl alcohol.
For consistency, melatonin, luzindole, 2-[125I]iodomelatonin and L-ascorbic acid were
first dissolved in 1 % ethyl alcohol and then added to Calcium-free Drosophila Ringer’s
solution (Ashburner, 1989). Concentrations of 2500 µM, 1000 µM, 500 µM, 100 µM,
and 50 µM melatonin were prepared to assay dose response.
Luzindole is a melatonin receptor antagonist for the human MT1 and MT2
receptors (pKi 6.2-6.8 and pKi 7.6-8.1 respectively) (Dubocovich, 1988).
2-[125I]iodomelatonin is a selective, high-affinity ligand for the identification and
characterization of melatonin receptor sites. The specific binding of
2-[125I]iodomelatonin fulfills all the criteria for binding to a receptor site, being stable,
reversible, saturable, and of high affinity (Dubocovich & Takahashi, 1987). The binding
affinity of 2-[125I]iodomelatonin to human MT1 and MT2 receptors displays values of
pKi 10.2-11.0 and pKi 9.7-10.3 respectively (Audinot et al., 2003). Single
68

concentrations of 2500 µM luzindole, and 1000 µM 2-[125I]iodomelatonin were
prepared. Based on the melatonin dose assay results, the standard concentration used
for ensuing experiments of melatonin and 2-iodomelatonin injections was 1000 µM. A
higher dose of (2500 µM) was used for luzindole to ensure that any melatonin receptors
present would be completely blocked by the antagonist.
Melatonin exhibits both receptor mediated and antioxidant mediated effects. As
a powerful antioxidant, melatonin has been shown to be more effective than vitamin C
(ascorbic acid) and vitamin E in combating paraquat induced oxidative stress in
Drosophila melanogaster (Bonilla et al., 2006). Injections with ascorbic acid in
Drosophila wild-type and slowpoke pupae will help to ascertain whether melatonin’s
effects on heart rhythmicity are receptor or antioxidant mediated.
Solutions were perfused directly over the pacemaker and caudal region of the
dorsal vessel by injection into the caudal end of the animal (Johnson et al., 1997). Glass
electrodes were used for injection and were pulled on a World Precision Instrument
PUL-100 micropipette puller. Tips were gently broken to assure sharpness.
Following a 10 minute pre-injection recording, the pupa was placed under an
Olympus dissecting scope for injection. A World Precision Instrument Nanoliter
Injector (model # A203XVY) was calibrated to administer 46 nl volume of liquid. A
micromanipulator was used to position the glass electrode in the dorsal posterior region
near the caudal region of the heart. Heartbeat was recorded for 10 minutes before
injection and for 10 minutes immediately (within 1 minute) after injection of a substance
as delineated above.
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Specifics of tests with luzindole
In addition to the protocol for melatonin and 2-[125I]iodomelatonin, CS, slo and
napts were subjected to the following protocol. After pre injection recording of
heartbeat, P1 pupae were injected with 46 nL of 2500 µM luzindole, then allowed 1.5
minutes of rest, and then injected with 46 nL of 1000 µM melatonin before post
injection heartbeat recording.
Owing to its clear, well-known and immediate effects of increased heart rate, I
used epinephrine and a beta-blocker (metoprolol) to establish the double injection
protocol. An initial 10 minute pre-injection recording of heart rate and rhythmicity was
performed.
Analysis of heartbeat data
See Materials & Methods, Chapter 1
Results
Effects of injections of melatonin alone and double injections with luzindole and
melatonin in wild type, slowpoke and napts pupae
Both wild-type and pupae bearing heart mutations injected with 1000 µM
melatonin showed significant increase in heart rhythmicity ranging from 54 to 91%
(Table 2.1 and Fig. 2.1)
When the same strains were injected first with 2500 µM luzindole, allowed to
rest for 1.5 minutes, and then injected with 1000 µM melatonin, a significant decrease in
heart rhythmicity was observed in wild-type pupae ( F(1,14) = 18.6; p < 0.001), but no
significant increase in heart rhythmicity (Table 2.2 and Fig. 2.1).
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Table 2.1 Effects of melatonin injection on heart rhythmicity in wild-type and heart
mutants

Canton-S (+)

1000

Mean
RI
Pre
25´C
0.449

napts

1000

0.406

0.746

+ 84%

30

0.02/0.01

(1,29) 338.6

< 2.2e-16 ***

slo

1000

0.357

0.681

+ 91%

42

0.02/0.01

(1,41) 61.4

9.29e-14 ***

Genotype

a

Mean
RI
Post
25´C
0.694

%
Change

N

+/-SEM
Pre/Post

F Value

P Value

+ 54%

30

0.02/0.02

(1,29) 158.7

<2.2e-16 ***

Concentration of melatonin injected

b
c

Meltonin
Injected
µmol-1a

Mean Rhythmicity Index pre-injection minutes 4-7

Mean Rhythmicity Index post-injection minutes 4-7

*** p < 0.001 comparing before injection to after melatonin injection within each strain

Table 2.2 Effects of double injection of luzindole and melatonin in heart rhythmicity in
wild-type and heart mutants

Genotype

Luzindole/
Meltonin
Injected
µmol-1

Mean
RI
Pre
25´C

Mean
RI
Post
25´C

%
Change

Canton-S (+)

2500/1000

0.583

0.480

napts

2500/1000

0.338

slo

2500/1000

0.378

a

P Value

- 18 %

15

0.03/0.03

(1,14) 18.6

3.78e-05 ***

0.288

-8%

5

0.03/0.05

(1,40 .001

0.970

0.346

-15%

10

0.03/0.03

(1,9) 3.7

0.0583

Concentrations of luzindole/melatonin injected

b
c

+/-SEM
Pre/Post

F Value

N

Mean Rhythmicity Index pre-injection minutes 4-7

Mean Rhythmicity Index post-injection minutes 4-7

*** p < 0.001 comparing before injection to after luzindole/melatonin injection within
each strain
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Figure 2.1 Effects of melatonin alone and luzindole/melatonin double injections on
heart rhythmicity in wild-type and heart mutants

Effects of ascorbic acid, 2-iodmelatonin and melatonin on heart rate and
rhythmicity in wild type and slowpoke pupae
Injection with 1000 µM 2-iodomelatonin, a high affinity melatonin agonist,
showed significant increase in heart rhythmicity between 53 % and 141 % in wild type
and slowpoke pupae respectively (p < 0.001) (Table 2.3 and Fig. 2.2, 2.3).
Ascorbic acid (vitamin C) is a powerful antioxidant. When 1000 µM
concentrations were injected into wild type and slowpoke pupae, no significant change
in heart rhythmicity was observed (Table 2.4, Fig 2.2, 2.3).
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Injections of 2-iodomelatonin had no significant effect on heart rate in either
wild type or slowpoke pupae (Table 2.5, Figs. 2.4, 2.5).
Injection of ascorbic acid showed significant decrease in heart rate in both wild
type and slowpoke pupae (p < 0.001) (Table 2.6, Figs. 2.4, 2.5).

Table 2.3 Effects of 2-Iodomelatonin injection on heart rhythmicity in wild-type and
slowpoke pupae

Canton-S (+)

1000

Mean
RI
Pre
25´C
0.519

slowpoke

1000

0.256

Genotype

a

Mean
RI
Post
25´C
0.796
0.618

%
Change

+/-SEM
Pre/Post

F Value

P Value

N

53%

5

0.03/0.01

(1,4) 30.3

6.92e-06 ***

141%

5

0.03/0.01

(1,4) 139.9

2.08e-12 ***

Concentration of 2-Iodomelatonin injected

b
c

2-Iodomelatonin
Injected
µmol-1a

Mean Rhythmicity Index pre-injection minutes 4-7

Mean Rhythmicity Index post-injection minutes 4-7

*** p < 0.001 comparing before injection to after 2-iodomelatonin injection within each
strain

Table 2.4 Effects of ascorbic acid injection on heart rhythmicity in wild-type and
slowpoke pupae
Ascorbic
Acid
Injected
µmol-1a

Mean
RI
Pre
25´C

Mean
RI
Post
25´C

Canton-S (+)

1000

0.551

0.513

slowpoke

1000

0.244

0.198

Genotype

a

+/-SEM
Pre/Post

F Value

N

-7 %

10

0.03/0.03

(1,9) 0.13

0.718

-19 %

10

0.03/0.02

(1,9) 1.6

0.217

Concentration of ascorbic acid injected

b
c

%
Change

Mean Rhythmicity Index pre-injection minutes 4-7

Mean Rhythmicity Index post-injection minutes 4-7
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P Value

Figure 2.2 Effects of ascorbic acid, 2-iodomelatonin and melatonin on heart
rhythmicity in wild-type pupae

Figure 2.3 Effects of ascorbic acid, 2-iodomelatonin and melatonin on heart
rhythmicity in slowpoke pupae
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Table 2.5 Effects of 2-iodomelatonin injections on heart rate in wild-type and slowpoke
pupae

Canton-S (+)

1000

Mean
Heart
Rate
Pre
25´C
2.26

slowpoke

1000

2.11

Genotype

a

Mean
Heart
Rate
Post
25´C
2.27
2.13

%
Change

N

+/-SEM
Pre/Post

F Value

P Value

0%

5

0.06/0.04

(1,4) 0.01

0.906

+1%

5

0.04/0.06

(1,4) 1.2

0.322

Concentration of 2-Iodomelatonin injected

b
c

2-Iodomelatonin
Injected
µmol-1

Mean heart rate pre-injection minutes 4-7

Mean heart rate minutes 4-7

Table 2.6 Effects of ascorbic acid injections on heart rate in wild-type and slowpoke
pupae

Canton-S (+)

1000

Mean
Heart
Rate
Pre
25´C
2.39

slowpoke

1000

2.18

Genotype

a

Mean
Heart
Rate
Post
25´C
2.25

1.86

%
Change

N

+/-SEM
Pre/Post

F Value

P Value

-6 %

10

0.04/0.04

(1,9) 22.2

1.38e-05 ***

-15 %

10

0.04/0.05

(1,9) 17.3

9.71e-05 ***

Concentration of ascorbic acid injected

b
c

Ascorbic
Acid
Injected
µmol-1

Mean heart rate pre-injection minutes 4-7

Mean heart rate minutes 4-7

*** p < 0.001 comparing before injection to after ascorbic acid injection within each
strain
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Figure 2.4 Effects of 2-iodomelatonin, ascorbic acid and melatonin injections on heart
rate in wild-type pupae

Figure 2.5 Effects of 2-iodomelatonin, ascorbic acid, and melatonin injections on heart
rate in slowpoke pupae
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Effects of melatonin injection on four different orphan receptor RNAi strains
crossed with GMH5-Gal4 heart driver
Repeated measures ANOVAs showed significant effects of melatonin injection
in CG3171, CG13579 and CG13575 orphan receptor strains (p < 0.05). This correlates
strongly with the results of absolute % increase in rhythmicity ranging from 20 to 38 %
in these three strains. These results indicate that no loss of function with melatonin
injection (Table 2.7, Fig. 2.6).
Upon initial testing, CG4313 showed promising results based on the strong but
not significant trend and 20 animals were tested (10 each of reciprocal crosses). Results
of melatonin injection with this orphan receptor RNAi continued to show no increase in
heart rhythmicity (p > 0.05) (Table 2.7, Fig. 2.6). This loss of function result implicates
that his CG4313 is a highly likely candidate for a melatonin receptor in Drosophila
melanogaster.
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Table 2.7 Effects of melatonin injection on heart rhythmicity in orphan receptor RNAi
crossed with GMH5-Gal4 driver
Orphan
Receptor
RNAi

Meltonin
Injected
µmol-1a
1000

Mean
RI
Prec
25´C
0.580

Mean
RI
Postd
25´C
0.588

CG4313a
CG4313b

1000

0.507

CG3171

1000

CG13579
CG13575

%
Change

N

+/-SEM
Pre/Post

F Value

P Value

+ 2%

10

0.04/0.03

(1,9) 0.12

0.730

0.494

- 2%

10

0.04/0.04

(1,9) 0.13

0.720

0.680

0.817

+20 %

5

0.03/0.04

(1,4) 12.2

0.00161 **

1000

0.649

0.817

+26 %

5

0.05/0.03

(1,4) 33.7

3.08e-06 ***

1000

0.491

0.679

+38%

5

0.07/0.04

(1,4) 14.2

0.000791 ***

a

orphan receptor RNAi virgin females crossed with GMH5 Gal 4 males

b

GMH5 Gal4 virgin females crossed with orphan receptor RNAi males

c

Mean Rhythmicity Index pre-injection minutes 4-7

d

Mean Rhythmicity Index post-injection minutes 4-7

** p < 0.01 comparing before injection to after melatonin injection within each strain
*** p < 0.001 comparing before injection to after melatonin injection within each strain
Figure 2.6 Effects of melatonin injection on heart rhythmicity in orphan receptor
RNAis crossed with GMHG-Gal 4 driver
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Discussion
In this set of experiments, I showed that melatonin’s ability to increase heart
rhythmicity in Drosophila melanogaster is a result of melatonin receptor binding. In the
process of elucidating melatonin’s effects, I also discovered an orphan G proteincoupled receptor that is highly likely to be a melatonin receptor. Evidence for these
findings stem from the results of three different experimental approaches. I showed:
1. A highly specific response to melatonin, 2. Effective blocking of melatonin’s effects
with its antagonist luzindole, 3. Mimicking of melatonin’s effects with its high-affinity
agonist 2-iodomelatonin, and 4. Loss of function using RNAi techniques to silence a
specific orphan GPCR.
The effects of the hormone melatonin on heart rhythmicity in Drosophila
melanogaster are profound. Though it is well known that Drosophila has receptors for
and produces its own serotonin, which is melatonin’s precursor, evidence for the
presence of melatonin receptors or endogenous production of melatonin in the fruit fly
has not been presented to date. Elucidation of whether melatonin’s effects on
Drosophila’s cardiovascular system are antioxidant mediated or receptor mediated is
crucial to unraveling the mystery of the mechanisms of this hormone.
In a previous set of experiments (Chapter 1) I demonstrated that melatonin was
able to increase heart rhythmicity by 54-104% without affecting heart rate in both wild
type and heart mutant strains of Drosophila melanogaster. This was an interesting
result, especially when compared to serotonin’s opposing effects of increasing heart rate
without significantly affecting heart rhythmicity (Johnson et al., 1997; VanKirk,
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unpublished manuscript). Since a melatonin receptor had not yet been identified in
Drosophila, it was not clear how melatonin was producing these effects. A handful of
studies have been carried out in vertebrates reporting the anti-arrhythmic properties of
melatonin (Benova et al., 2013, 2015; Bertuglia & Reiter, 2007; Diez et al., 2009; Vazan
et al., 2005), but most researchers attributed this effect to melatonin’s ability to scavenge
reactive oxygen species (ROSs) produced during myocardial injury.
It seemed a logical next step to introduce a melatonin antagonist in my
experimental design in order to gain a better understanding of melatonin’s activity. In
this set of experiments I performed double injections of the non-competitive melatonin
antagonist, luzindole and melatonin. Not only did luzindole completely abolish
melatonin’s anti-arrhythmic effects in wild type, slo and napts pupae, it also showed a
slight , but non-significant decrease in heart rhythmicity when injected alone in wildtype and napts pupae and a significant decrease in heart rhythmicity in slo pupae. This
would make sense if Drosophila makes melatonin endogenously as luzindole would be
blocking its effects as well. This antagonist effect of luzindole can only be exerted
through receptor-mediated activity, which strongly implicates the presence of melatonin
receptors in Drosophila melanogaster.
In a similar group of experiments designed to support the earlier findings, I chose
to inject wild type and slo pupae with the high-affinity melatonin agonist, 2Iodomelatonin. Results of these experiments showed that 2-Iodomelatonin increased
heart rhythmicity in slo pupae by 50% more than melatonin, respectively. These results
are consistent with the fact that 2-Iodomelatonin shows higher binding affinity to
melatonin receptors (MT1 and MT2) than melatonin itself (Audinot et al., 2003). As
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was the case with luzindole, 2-Iodomelatonin is only able to exert its effects by binding
to a melatonin receptor, which these results strongly support. This is another clear
indication that a melatonin receptor exists in Drosophila melanogaster.
Melatonin’s cardio-protective effects are known to be antioxidant-related
(Reviews: Reiter & Tan, 2003; Tengattini et al., 2007). At present there are several
lines of evidence which suggest that an increased intake of antioxidants, vitamins,
ascorbic acid (C), tocopherols (E), and beta-carotene (A), have some protective role in
the coronary heart disease and other cardiovascular problems (Zhang et al., 2014). In
support of melatonin’s anti-arrhythmic effects being receptor-mediated and not
antioxidant- mediated, I designed experiments to inject concentrations of ascorbic acid
(vitamin C) into Drosophila pupae. Results of ascorbic acid injections showed a 5% and
24% decrease in heart rhythmicity in wild type and slo pupae, respectively. Even
though Eslami et al., 2007, report that ascorbic acid, when used as an adjunct to ßblockers, is highly effective at reducing post-operative atrial fibrillation, its antioxidant
properties do not seem to have the same effect on the Drosophila heart. Instead, these
results disprove the hypothesis that melatonin’s anti-arrhythmic effects are antioxidant
related. Furthermore, studies in vertebrates implicating that melatonin’s anti-arrhythmic
effects are antioxidant-mediated did not include the use of luzindole in their
experimental design (Benova et al., 2013, 2015; Bertuglia & Reiter, 2007; Diez et al.,
2009; Vazan et al., 2005).
Mammalian melatonin receptors are members of the G protein-coupled receptor
family. GPCRs represent the largest superfamily and most diverse group of mammalian
transmembrane proteins. The main characteristic feature of these proteins is that they
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share a common seven-transmembrane (7TM) configuration (Tang et al., 2012). A
broad range of ligands can bind to GPCRs, which result in a variety of signal
transduction pathways that influence numerous physiological pathways in the body.
GPCRs are the most prominent family of pharmacological targets in biomedicine
(Lappano & Maggiolini, 2011).
The rhodopsin-like (Class A) receptors are the largest and most extensively
studied subfamily of GPCRs. Both serotonin (5-HT) receptors and melatonin receptors
in vertebrates and serotonin receptors in Drosophila fall into this category, so it is
reasonable to assume that possible melatonin receptors in the fruit fly would also be of
this type. The Drosophila melanogaster genes CG4313, CG3171, CG13575 and
CG13579 code for putative neuropeptide receptors belonging to class A are still orphans
(Hauser et al., 2006). Bloomington stock center has RNAi strains for the
aforementioned genes that can knock down the gene of interest in specific tissues and be
used for loss of function tests.
In my final set of experiments I crossed the RNAi strains of four different
Drosophila orphan GPCRs (CG4313, CG3171, CG13575, CG13579) with the heart
specific Gal 4 driver, GMH5 in order to silence the orphan receptor in question and
carry out loss of function tests. Injection of melatonin into CG3171, C13575 and
CG13579 crosses all showed significant increase in rhythmicity. Because RNA
interference knocks down the gene coding the orphan receptor, an increase in
rhythmicity with melatonin injection indicates that the melatonin receptor is still present
and is not coded for by the targeted gene. However, injections of melatonin into the
CG4313 silenced pupae showed no significant increase in heart rhythmicity, which
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indicates that the CG4313 orphan receptor could be a melatonin receptor. Interestingly,
of the four orphan receptors tested, the CG4313 orphan receptor also shows the highest
homology (~ 30%) to the human melatonin receptor.
In summary, the combination of pharmacology and genetics described above
provide data that support the receptor mediated anti-arrhythmic effects of melatonin and
the presence of a melatonin receptor in Drosophila melanogaster. Coupling a ligand
such as melatonin to an orphan receptor will provide invaluable information as to the
signaling pathway that underlies melatonin’s anti-arrhythmic effects.
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APPENDIX
THE RELATIONSHIP OF HEART FUNCTION TO TEMPERATURE IN
Drosophila melanogaster AND ITS HERITABILITY
Abstract
We measured heart rate and rhythmicity (regularity) of heartbeat in Drosophila
melanogaster at five different temperatures (20, 25, 30, 35, and 37 C.), for a Florida
population and estimated the narrow-sense heritability of both traits. Heritability of
heart rate ranged from 0.16 to 0.24, but was statistically significant only at 20 (h2 =
0.24) and at 30 (h2 = 0.23). The heritability of heartbeat rhythmicity ranged from –
0.034 to 0.11, and was not significant at any temperature. Heart rate increased linearly
with increasing temperature; the temperature-dependence of heart rate was itself
heritable (h2 = 0.29). Heart rhythmicity varied curvilineanearly and was wellrepresented by a parabolic function, peaking at about 27 suggesting a temperature
optimum. The regularity of the heartbeat did not covary with heart rate except at 20.
Neither heart rate nor regularity covaried with the change in heart rate with temperature.
For this population of D. melanogaster, we conclude that there is substantial genetic
variation for the mechanism whereby the cardiac pacemaker reacts to changes in
temperature, but not for the cardiac pacemaker's rhythmicity. The small values of h2 for
temperature-specific heart rate and heartbeat rhythmicity suggest that these traits are
adaptive.
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Introduction

The Drosophila heart, or dorsal vessel, is located medially and dorsally in the
hemocoel and transports hemolymph through the larval and adult body cavity (Miller,
1950; Rizki, 1978; Curtis et al., 1999). The anterior third of the dorsal vessel forms the
aorta. The posterior segment, or heart proper, contains three pairs of openings called
ostia to admit hemolymph
( Rizki, 1978; Curtis et al., 1999; Wasserthal, 2007). Heart pacemaking in Drosophila is
myogenic (Dowse et al., 1995; Gu & Singh, 1995; Bodmer et al., 2005) , and originates
from a caudal pacemaker (Rizki, 1978), an assembly of ion channels, including those
passing Ca2+ and K+, interacting in an oscillatory manner (Dowse et al., 1995; Johnson
et al., 1998; Bodmer et al., 2005). The beat consists of a contraction phase (systole) and
a relaxation phase (diastole) ( Rizki, 1978; Curtis et al., 1999; Wasserthal, 2007).
Heartbeat may reverse requiring nervous control of a second anterior pacemaker (Dulcis
& Levine, 2003; Wasserthal, 2007).
Increasing temperature raises heart rate in the fly (Rizki, 1978; White et al.,
1992; Dowse et al., 1995; Ashton et al., 2001; Ray & Dowse, 2005). The precise
mechanism of this change is not understood. It is of considerable interest to know how
the heart reacts to temperature changes and what factors influence any such reactions.
That there may be a strong genetic component is suggested by tests of flies bearing the
mutations no action potentialTS (napTS) and slowpoke (slo), phenotypes of which include
attenuation or elimination of the response of the heart to temperature (Dowse et al.,
1995; Johnson et al., 1998). Using a deficiency screen QTL approach,
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Ashton et al., (2001) identified nine areas of the genome that either increased or
decreased P1 heart rate.
There appears to be one report of narrow-sense heritability of heart rate for D.
melanogaster (Robbins et al., 1999). They measured heart rate in inbred lines from
many geographic locations, and therefore this work gives an estimate that includes
variation between as well as within a population. Temperature in this work was likely
ambient. Because both the rate and the regularity of the heartbeat in Drosophila are
temperature-sensitive, we monitored heart function in a single population at five
temperatures across the wide range of 20 to 37, and determined narrow-sense
heritabilities of these traits within and across temperatures.
Materials and Methods
Fly culture and the experimental population
A laboratory population was established by mass-mating the progeny of 35 wild,
inseminated D. melanogaster females collected in Tampa, Florida. Thereafter, the
population was maintained in twelve 250-ml culture bottles containing malt-molassesyeast-cornmeal-agar medium (0.5% propionic acid added to the medium to control mold
growth). A Tomac® tissue was added to each culture bottle to promote pupation out of
the culture medium. Flies were cultured at 25 C in a 12:12 Light:Dark cycle in a
humidified incubator. Approximately 200 adults were transferred to fresh medium in
each bottle when subculturing.
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As necessary, adults were sexed under CO2 anesthesia. Adults were transferred
either by tapping groups from one culture vessel to another or by gentle aspiration of
individuals.
Individual crosses were carried out in 35-ml vials, using the same culture
conditions as described above, but without a tissue added to the medium.
Measurement of heartbeat
All test subjects were collected at the third-instar larval stage just as they were
entering the early pupal (P1) stage. At this point, they are translucent, making any heart
movements transmitted to the surrounding organs easily visible. Each pupa was placed
on a glass slide in a drop of distilled water and set in the light beam of an Olympus
binocular microscope. The light source was powered by a DC supply to eliminate 60 Hz
variation. The water served to increase the brilliance of the illumination passing through
the pupa, and also helped in heat transfer from the slide as the temperature was varied.
The pupa was adjusted so that one clear portion of the abdomen filled the field of view
with just the surrounding fat bodies visible. The movement of these organs results in a
variation in illumination that can be detected by a phototransistor. This signal is
amplified and recorded in a microcomputer through a DAS8 AD converter.
Temperature of the slide was maintained with a Sensortek TS-4 unit, however it was not
possible to record temperatures within the animals. Recording was done at five
different temperatures (20, 25,  30, 35, 37). For each pupa, 30 seconds of recording
was performed at each temperature. In between measurements 1.5 minutes of
acclimation time was allowed.
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Analysis of heartbeat
Data from individual flies taken at each temperature were analyzed by
autocorrelation (Chatfield, 1980) and Maximum Entropy Spectral Analysis (MESA)
( Ulrych & Bishop, 1975; Dowse & Ringo, 1989; Levine et al., 2002; Dowse, 2009).
Estimates of heart rate were based on the spectral analysis, autocorrelation, and
inspection of the raw data plots.
Rhythmicity of heartbeat results in recurring positive and negative peaks in the
autocorrelogram, and the decay envelope reflects regularity in the signal (Chatfield,
1980). The value of the correlation coefficient at the second peak is the rhythmicity
index. The value at lag zero is always one (Dowse et al., 1995; Levine et al., 2002;
Dowse, 2009). Empirically, we observe that as rhythmicity index decreases, there are
more skipped beats, irregular intervals between beats, periods of heartbeat cessation, and
rate variations with time (Johnson et al., 2000; Levine et al., 2002; Dowse, 2009).
The temperature-dependences of heart rate and rhythmicity index were estimated
for each individual from least-squares regression (temperature on heart rate or
rhythmicity index); the resulting slopes were our measures of each phenotype. We also
did this regression for all individuals pooled together across families to get values for the
entire population.
We tested whether there was a relationship between frequency of heartbeat and
the rhythmicity index at each of the test temperatures. We also queried whether either
frequency or rhythmicity of heartbeat were related to the slope of the regression line of
temperature on frequency at the temperature at which the hearts were most rhythmic,
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25. We computed correlation coefficients (r) individually in EXCEL for each of the
above interactions across all test animals and asked if r > 0 using a two-tailed t-test
(Schefler, 1969) (N = 317, df = 315, t = 1.968).
Crosses and heritability
The heartbeat of white pupae randomly selected from the general stock
population was measured without knowing sex. Each pupa was reared in isolation in a
35-ml culture vial. Families were established from these individuals. When these flies
eclosed, individual virgin pairs were isolated as parents of families to be tested further.
Each such family was reared in a 35-ml culture vial. Heartbeat was monitored in four
randomly selected offspring of each family when those offspring reached the white pupa
stage. Fifty families were so studied.
At each temperature, narrow-sense heritability (h2) was calculated for heart rate
and rhythmicity by least squares regression of the mean parental (mid-parent) values on
the means of the four offspring within a family. The slope of this regression line is the
estimate of h2 (Falconer, 1960). Further, we estimated the heritability of the response to
temperature by calculating mid-parent and mean offspring values for each family from
the slopes derived from the individual regressions of temperature on rate and
rhythmicity for each individual. We then regressed mean mid-parent values on mean
offspring values. In all tests of significance, α = 0.05.
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Results
Effects of temperature on heart rate frequency and rhythmicity
Across the range tested for all subjects pooled, heart rate increases monotonically
with temperature and is well-represented by a straight line (slope = 0.09; intercept =
0.23; r2 = 0.67) (Fig. A.1a). Given the strength of this linear relationship, we tested the
fit of the data according to the method of Arrhenius wherein ln(rate) = lnA – Ea/RT,
where A is the “pre-exponential”, or intercept of the plot, Ea is the activation energy of
the system in Kcalmol-1, T is the temperature in K, and R is the gas constant (1.985877
calK-1 mol-1) (Pilling & Seakins, 1996). Arrhenius plots have been shown to be of use
in other than studies of simple chemical reaction, having been applied to a wide range of
processes ranging from cricket chirping to the rate of heartbeat in the terrapin (Laidler,
1972). The regression of 1/T on ln(rate) is a good fit (r2 = 0.64). This yields an
activation energy of ~6000 Kcalmol-1. The Q10 for this relationship across the common
physiological range of 20 to 30 is 1.44. (Q10 = heart rate at 30/heart rate at 20.)
We did a similar analysis for all animals across temperature for the rhythmicity
index. This statistic has a nonlinear relationship to temperature, highest in the midrange between 25º and 30º C, falling off at the extreme temperatures. We did linear
regression, and find there is a weakly significant linear relationship (r2 = 0.03), but
clearly this is not a good description of the data. We next fit a parabola to the data
which offers an exceptionally good representation (r2 = 0.88). The estimated peak
occurs at ~27º (Fig A.1b).
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Correlations among heart rate, rhythmicity index and response to changing
temperature
There was a significant correlation between heart frequency and rhythmicity
index only at 20º (r = 0.252, t = 4.62) (See materials and Methods above for details of
test). Relationships at all other temperatures were not significant (25º: r = 0.056, t =
0.99; 30º: r = 0.024, t = 0.4366: 35º, r = -0.029: t = -0.515; 37º: r = -0.077, t = -1.37).
At 25º, at which temperature the rhythmicity index was near maximum, frequency of
heartbeat is not correlated with the slope of the regression line (r = 0.135, t = 0.135), nor
is rhythmicity index (r = -0.08, t = -0.08) (see Materials and Methods above for details
of test).
Heritability of heart rate, rhythmicity, and temperature-dependence of heart rate
Heritability of heart rate calculated at the five test temperatures ranged from 0.16
to 0.24, and the heritability of the heartbeat rhythmicity index ranged from –0.034 to
0.11; Table A.2. Heritability of heart rate was statistically significant (based on
significance of the regression analysis itself) at 20 (h2 = 0.24) and at 30 (h2 = 0.23);
Table A.1. The estimates of heritability of rhythmicity index was not significant at any
temperature (Table A.2).
In the test of heritability of response to change in temperature, in which we
regressed mean filial slopes for each family on mid parent values, we found a clear
result. A significant portion of the variance among slopes was genetic: h2 = 0.29, r2 =
0.08, t = 2.398, df = 50, P = 0.02 (Figure A.3)
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Table A.1. Heritabilities for heart rate.

Temperature Heritability
(h2)

r2

t value

Degrees of
freedom (df)

P value

20ºC

0.239*

0.18

3.414

50

0.001

25ºC

0.170

0.03

1.759

50

0.085

30ºC

0.230*

0.08

2.308

50

0.025

35ºC

0.165

0.03

1.586

50

0.119

37ºC

0.178

0.05

1.875

50

0.067

r2

t value

Degrees of
freedom (df)

P value

*Significant

Table A.2 Heritabilities for rhythmicity indices.
Temperature Heritability
(h2)
20ºC

-0.034

-0.02

-0.311

50

0.757

25ºC

0.019

-0.02

0.231

50

0.818

30ºC

0.110

-0.01

0.854

50

0.397

35ºC

0.057

-0.01

0.599

50

0.551

37ºC

0.083

0.00

0.884

50

0.381
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FIGURE LEGENDS
Figure A.1. Response of heart rate and rhythmicity to change in temperature. (a)
Regression of temperature on frequency for all animals (N=300, r2 = 0.67).
Parameters of regression equation shown bottom right. Means indicated by diamond
symbols,  S.D. Regression equation: y = 0.09x + 0.024. b) Results of nonlinear
regression, fitting a parabola to the rhythmicity index as a function of temperature for all
flies (N = 300, r2 = 0.88). Means indicated by diamond symbols,  S.D. Regression
equation: y = -0.0018(x – 26.94)2 + 0.7.

Figure A.2. Regression analyses of mid parent heart rate on mean offspring heart rate.
This analysis yields narrow-sense heritability of the trait, h2. (a) 20ºC (Equation: y =
0.24x + 1.48). (b) 30ºC (Equation: y = 0.23x + 2.2). Regressions done at 25ºC, 35ºC and
37ºC were not significant (data not shown).

Fig A.3. Regression of mid-parent on filial mean slopes derived from individual
regressions of temperature on heart rate for all flies. The narrow-sense heritability of the
response to temperature was significant. Parameters of the regression equation are
shown bottom right. h2 = 0.29. Regression equation: y = 0.29x + 0.07.
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Figure A.1 Response of heart rate and rhythmicity to change in temperature

a) Regression of temperature on frequency for all animals

b) Results of nonlinear regression, fitting a parabola to the rhythmicity
index as a function of temperature for all flies
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Figure A.2 Regression analyses of mid parent heart rate on mean offspring heart
rate

a) At 20 ̊ C

b) At 30 ̊ C
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Figure A.3 Regression of mid-parent on filial mean slopes derived from individual
regressions of temperature on heart rate for all flies
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Discussion
In D. melanogaster, heart rate increased with increasing temperature, a result
consistent with previous fly studies (Rizki, 1978; Dowse et al., 1995; Ashton et al.,
2001; Ray & Dowse, 2005) and studies in other insects (Crozier & Federighi, 1925;
Fries, 1926). This is to be expected for poikilotherms, in which the rate of most
physiological processes vary positively with temperature (Sweeny & Hasting, 1960;
Winfree, 1980). In contrast, heart rhythmicity varied with temperature in a non-linear
way: it was lower at extreme temperatures than at intermediate temperatures, the latter
being close to the optimum for the survival and reproduction of this species (Ashburner,
1989). It is provocative that two important characteristics of heart function, rate and
regularity, have very different relationships to changes in temperature as shown in Fig.
A.2.
Narrow-sense heritability of heart rate in the Florida population ranged between
0.16 and 0.24 and was temperature-dependent. The two largest heritabilities for this trait
were for heartbeat measured at 20 (h2 = 0.24) and 30 C (h2 = 0.23). For the other
temperatures, heritability was not statistically significant, though that may reflect the
low statistical power of the experimental design. In contrast, narrow-sense heritability
of the rhythmicity of heartbeat was much lower (range: X to Y) and it was not
significant at any temperature. A perhaps surprising and provocative finding was the
discovery that the response of heart rate to temperature was itself heritable (h2 = 0.29).
Robbins et al. (1999), reported a heritability of heart rate of 0.30. In that study
the estimate was based on variation among inbred lines, some derived from a Michigan
population and others based on strains collected at other, widely separated geographic
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locations. Consequently, the earlier study gave an estimate of heritability which, if not
species-wide, represents inter-population variability in addition to variation within a
population. Also, if there is substantial epistatic variance for heart rate in this species, a
heritability estimate based on variance among inbred strains would have included this
variance as well as additive variance. Regression of offspring mean on parental mean
contains a fraction (viz. ¼) of additive X additive interaction variance. It remains to be
determined how much genetic variance is due to epistasis. Another difference between
this report and that of Robbins et al. (1999), relates to temperature. In both studies, flies
were cultured at 25 C, which is thought to be close to the optimal rearing temperature
for this species (Ashburner, 1989). However, in the present study, heart rate was
measured at five different temperatures, and each temperature was precisely maintained,
while Robbins et al. (1999),

presumably recorded at ambient. Despite the

methodological differences between the two studies, the heritabilities are reasonably
similar.
Robbins et al. (1999), pointed out that the ability of a heart to beat regularly at a
certain rate is a remarkable phenotype, and one that reflects genetic regulation. The
heritabilities reported here bear out this statement, especially the very low values
measured for heartbeat rhythmicity. Even the largest heritability we measured, for
temperature-dependence of heart rate, the size of h2 was modest (0.29). Natural
selection within a population reduces the amount of additive genetic variation for the
trait under selection. While a paucity of additive genetic variation for a trait does not
imply that the trait has been subjected to natural selection, the converse is true: a large
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amount of additive genetic variation for a trait implies that it has not been under strong
directional selection.
Ultimately, changes in heart rate must, perforce, be mediated through modulation
of transmembrane potentials in the pacemaker (Bodmer et al., 2005). This may be a
direct effect of temperature. In insects, the heart itself is heated or cooled according to
ambient temperature and metabolic activity. It may be that varying temperatures alter
state variables of the oscillating ensemble of ion channels comprising the pacemaker.
The activation energy estimated from the Arrhenius plot is of interest in this regard, as it
suggests that covalent bonds are not being broken (Laidler, 1972). The Q10 is also fairly
low.
Most metabolic reactions experience a rate increase when exposed to increasing
temperatures (Sweeny & Hasting, 1960). However, a surprising range of metabolic
processes are seen to be unresponsive to temperature change, i.e. must be compensated
in some way (Bullock, 1955; Winfree, 1980). For example, circadian clock oscillators
in Drosophila, are seen to have a nearly flat temperature response (Pittendrigh, 1954). If
this be the case for the heart, the pacemaker might, at least in part, be indirectly affected
by temperature, perhaps through neurotransmitter control. Previous work in other
insects supports this interpretation. In order for an insect to respond to variations in both
internal and external conditions, its heart rate must be variable and under control. In the
moth, circulation of haemolymph may be thermoregulatory, and increasing heart rate in
response to raised temperatures is a result of involvement of the nervous system in
sensing heat and controlling rate (Miller, 1985). Heinrich (1970a,b), has demonstrated
such thermoregulation in Manduca sexta. When the thorax overheats, the heart responds
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by increased pumping of hemolymph into the abdomen, a response eliminated by
sectioning of the ventral nerve cord. The site of the thermoregulation was traced to the
pterothoracic ganglia in Cecropia moths by artificial thermal clamping (Hanegan, 1973).
Desert robber flies, Promachus gigantius and Efferia texana were shown to
thermoregulate, but with differences related to body mass (Morgan & Shelley, 1988).
Such putative indirect effects would likely be mediated via diffusible
transmitters acting upon ionotropic receptors, or through networks of intracellular
signaling pathways leading to biochemical modifications of pacemaker components
(Bodmer et al., 2005). The neurotransmitters norepinephrine, serotonin, dopamine, and
acetylcholine are cardioacceleratory (Johnson et al., 1997). Limulus GHSLLHFamide
(Gaus et al., 1994; Johnson et al., 2000; Bodmer et al., 2005). The catecholamines may
act through G-Protein coupled receptors, which is the case in vertebrates (Hartzell, 1988;
Trautwein & Hescheler, 1990). cGMP is implicated in at least one control pathway as
non-hydrolyzable forms (Brautigan & Pinault, 1991) increase heart rate in the fly
(Johnson et al., 2002). Drosophila homozygous for the sitter allele of the foraging gene
(Sokolowski, 2001; de Belle et al., 1989), which encodes a cGMP-dependent kinase
(Osborne et al., 1997), have accelerated heart rate (Johnson et al., 2002). Heart
Rhythmicity Index was affected by pertussis toxin and by agonists and antagonists of
both  adrenergic and 5-HT2 receptors; this suggests involvement of two different types
of G proteins (Johnson et al., 2002). Pacemaker sensitivity to serotonin was eliminated
in animals heterozygous for the homozygous-lethal mutation l(4)16, an allele of the gene
that encodes CaM-kinase-II (Hochman, 1971; Cho et al., 1991; Ohsako et al., 1993;
Griffith et al., 1993). Norepinephrine sensitivity was unaffected (Johnson et al., 2002).
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Identical results were obtained when flies were treated with the CaM-kinase-II inhibitor
KN-93 (Johnson et al., 2002).
White et al. (1992) tested for effects of heavy water consumption (water
containing deuterium, 1H2, or D2O) and temperature change on heart rate. D2O reduced
heart rate at all temperatures tested. Heart rate rose linearly between 18 and 33 in flies
drinking protonated water. This held for D2O concentrations of 20% and 40%, but the
D2O reduced the sensitivity to the temperature changes as the slopes flattened
proportionally at each concentration indicating an interaction between the two
treatments of an unknown nature.
Human cardiovascular function is influenced by multiple genetic factors and
knowing about the underlying genetic variation in these traits can be useful in medicine
and health care (Broeckel & Schork, 2004; Lusis et al., 2004; Wilson & Olden, 2004).
Findings in the fly are directly applicable to the human heart as a growing number of
genes have been identified with homologous function in both organisms (Bodmer et al.,
2005).
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